WO2001072265A1 - Preparation externe pour la peau et agents d'embellissement - Google Patents
Preparation externe pour la peau et agents d'embellissement Download PDFInfo
- Publication number
- WO2001072265A1 WO2001072265A1 PCT/JP2001/002787 JP0102787W WO0172265A1 WO 2001072265 A1 WO2001072265 A1 WO 2001072265A1 JP 0102787 W JP0102787 W JP 0102787W WO 0172265 A1 WO0172265 A1 WO 0172265A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- physiologically acceptable
- skin
- erythrodiol
- maslinic acid
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 141
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 claims abstract description 207
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 claims abstract description 207
- 150000003839 salts Chemical class 0.000 claims abstract description 192
- PSZDOEIIIJFCFE-UHFFFAOYSA-N Oleanolic alcohol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C)(C)CC5C4=CCC3C21C PSZDOEIIIJFCFE-UHFFFAOYSA-N 0.000 claims abstract description 107
- HTZRWCSRPTWJCT-UHFFFAOYSA-N erythrodiol Natural products CC1(C)CCC2(CO)CCC3C(CCC4C3(C)CCC5C(C)(C)C(O)CCC45C)C2C1 HTZRWCSRPTWJCT-UHFFFAOYSA-N 0.000 claims abstract description 107
- PSZDOEIIIJFCFE-OSQDELBUSA-N erythrodiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PSZDOEIIIJFCFE-OSQDELBUSA-N 0.000 claims abstract description 99
- 150000001875 compounds Chemical class 0.000 claims abstract description 41
- 230000002087 whitening effect Effects 0.000 claims description 241
- 239000002253 acid Substances 0.000 claims description 187
- 239000003795 chemical substances by application Substances 0.000 claims description 126
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 94
- 239000000203 mixture Substances 0.000 claims description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 66
- 240000007817 Olea europaea Species 0.000 claims description 63
- 239000003960 organic solvent Substances 0.000 claims description 46
- 239000003921 oil Substances 0.000 claims description 41
- 235000019198 oils Nutrition 0.000 claims description 41
- 238000004519 manufacturing process Methods 0.000 claims description 36
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 28
- 230000015572 biosynthetic process Effects 0.000 claims description 27
- 239000004006 olive oil Substances 0.000 claims description 26
- 235000008390 olive oil Nutrition 0.000 claims description 26
- 239000004480 active ingredient Substances 0.000 claims description 24
- 238000000746 purification Methods 0.000 claims description 23
- 239000006210 lotion Substances 0.000 claims description 22
- 239000007844 bleaching agent Substances 0.000 claims description 21
- 238000005194 fractionation Methods 0.000 claims description 18
- 230000008099 melanin synthesis Effects 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 14
- 229930014626 natural product Natural products 0.000 claims description 13
- 230000017531 blood circulation Effects 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 10
- 235000002020 sage Nutrition 0.000 claims description 10
- 239000012190 activator Substances 0.000 claims description 9
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 239000003906 humectant Substances 0.000 claims description 8
- 244000294611 Punica granatum Species 0.000 claims description 7
- 235000014360 Punica granatum Nutrition 0.000 claims description 7
- 240000008866 Ziziphus nummularia Species 0.000 claims description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 244000025221 Humulus lupulus Species 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000002736 nonionic surfactant Substances 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 244000301850 Cupressus sempervirens Species 0.000 claims description 3
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 2
- 240000008620 Fagopyrum esculentum Species 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 2
- 239000004020 conductor Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 abstract description 4
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 abstract description 4
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 abstract description 4
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 abstract description 4
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 abstract description 4
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 abstract description 4
- XUARCIYIVXVTAE-ZAPOICBTSA-N uvaol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C XUARCIYIVXVTAE-ZAPOICBTSA-N 0.000 abstract description 4
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 abstract description 3
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 abstract description 3
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 abstract description 3
- SYFNOXYZEIYOSE-UHFFFAOYSA-N uvaol Natural products CC1CCC2(O)CCC3(C)C(=CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C SYFNOXYZEIYOSE-UHFFFAOYSA-N 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 182
- 235000002639 sodium chloride Nutrition 0.000 description 165
- -1 friedelane triterpenes Chemical class 0.000 description 81
- 235000019441 ethanol Nutrition 0.000 description 71
- 150000003648 triterpenes Chemical class 0.000 description 63
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 239000000284 extract Substances 0.000 description 53
- 239000000047 product Substances 0.000 description 48
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 238000009472 formulation Methods 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 35
- 230000000694 effects Effects 0.000 description 31
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 26
- 230000002401 inhibitory effect Effects 0.000 description 26
- 238000011282 treatment Methods 0.000 description 26
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 24
- 241000196324 Embryophyta Species 0.000 description 24
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 24
- 238000000605 extraction Methods 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- 239000002537 cosmetic Substances 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 230000006870 function Effects 0.000 description 21
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
- 239000000839 emulsion Substances 0.000 description 20
- 238000011156 evaluation Methods 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000004137 magnesium phosphate Substances 0.000 description 18
- 229960002261 magnesium phosphate Drugs 0.000 description 18
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 18
- 235000010994 magnesium phosphates Nutrition 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 17
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 17
- 239000000843 powder Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 235000014113 dietary fatty acids Nutrition 0.000 description 16
- 229930195729 fatty acid Natural products 0.000 description 16
- 239000000194 fatty acid Substances 0.000 description 16
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 16
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 15
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 15
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 15
- 230000003833 cell viability Effects 0.000 description 14
- 239000006071 cream Substances 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 206010014970 Ephelides Diseases 0.000 description 13
- 208000003351 Melanosis Diseases 0.000 description 13
- 239000000049 pigment Substances 0.000 description 13
- 229940058015 1,3-butylene glycol Drugs 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 229930003268 Vitamin C Natural products 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 12
- 235000019437 butane-1,3-diol Nutrition 0.000 description 12
- 239000012141 concentrate Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 235000019154 vitamin C Nutrition 0.000 description 12
- 239000011718 vitamin C Substances 0.000 description 12
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 229930182470 glycoside Natural products 0.000 description 11
- 150000002338 glycosides Chemical class 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 11
- 150000001298 alcohols Chemical class 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 235000019341 magnesium sulphate Nutrition 0.000 description 10
- 239000002674 ointment Substances 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 208000001382 Experimental Melanoma Diseases 0.000 description 9
- 241000219745 Lupinus Species 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 235000013399 edible fruits Nutrition 0.000 description 9
- 239000003205 fragrance Substances 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000000061 acid fraction Substances 0.000 description 8
- 229960000271 arbutin Drugs 0.000 description 8
- 239000007795 chemical reaction product Substances 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 230000003405 preventing effect Effects 0.000 description 8
- 235000013772 propylene glycol Nutrition 0.000 description 8
- 229960004063 propylene glycol Drugs 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 230000000475 sunscreen effect Effects 0.000 description 8
- 239000000516 sunscreening agent Substances 0.000 description 8
- 208000012641 Pigmentation disease Diseases 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 229920002125 Sokalan® Polymers 0.000 description 7
- 235000021355 Stearic acid Nutrition 0.000 description 7
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 150000002430 hydrocarbons Chemical class 0.000 description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 7
- 230000019612 pigmentation Effects 0.000 description 7
- 239000008117 stearic acid Substances 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000287 crude extract Substances 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 150000002016 disaccharides Chemical class 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000000419 plant extract Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- AAPLIUHOKVUFCC-UHFFFAOYSA-N trimethylsilanol Chemical compound C[Si](C)(C)O AAPLIUHOKVUFCC-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 5
- 239000004166 Lanolin Substances 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 206010042496 Sunburn Diseases 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 239000006096 absorbing agent Substances 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 125000004849 alkoxymethyl group Chemical group 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 5
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 5
- 229960004705 kojic acid Drugs 0.000 description 5
- 235000019388 lanolin Nutrition 0.000 description 5
- 229940039717 lanolin Drugs 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 150000002772 monosaccharides Chemical class 0.000 description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 229940032094 squalane Drugs 0.000 description 5
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- 102000004882 Lipase Human genes 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 238000003953 normal phase liquid chromatography Methods 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 229920003169 water-soluble polymer Polymers 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 3
- 235000018185 Betula X alpestris Nutrition 0.000 description 3
- 235000018212 Betula X uliginosa Nutrition 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 235000010523 Cicer arietinum Nutrition 0.000 description 3
- 244000045195 Cicer arietinum Species 0.000 description 3
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 3
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 3
- 244000020551 Helianthus annuus Species 0.000 description 3
- 235000003222 Helianthus annuus Nutrition 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000207836 Olea <angiosperm> Species 0.000 description 3
- 235000002725 Olea europaea Nutrition 0.000 description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 3
- 240000004371 Panax ginseng Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000021536 Sugar beet Nutrition 0.000 description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229910052797 bismuth Inorganic materials 0.000 description 3
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 3
- 229910000072 bismuth hydride Inorganic materials 0.000 description 3
- BPBOBPIKWGUSQG-UHFFFAOYSA-N bismuthane Chemical compound [BiH3] BPBOBPIKWGUSQG-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 235000017803 cinnamon Nutrition 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 239000007854 depigmenting agent Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000010445 mica Substances 0.000 description 3
- 229910052618 mica group Inorganic materials 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 3
- 229940100243 oleanolic acid Drugs 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000015170 shellfish Nutrition 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- ZASJRRFAYSNSHU-UHFFFAOYSA-N 65995-62-2 Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1C1=C(O)C(O)=C(OC2=O)C3=C1C(=O)OC1=C3C2=C(C=2C(=CC(O)=C(O)C=2O)C(O)=O)C(O)=C1O ZASJRRFAYSNSHU-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 235000021357 Behenic acid Nutrition 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- 235000008694 Humulus lupulus Nutrition 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000237852 Mollusca Species 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 229940092738 beeswax Drugs 0.000 description 2
- 229940116226 behenic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000003327 cancerostatic effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 229940105990 diglycerin Drugs 0.000 description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 2
- ILLRQJVNDWDWBA-UHFFFAOYSA-K dimagnesium;phosphate Chemical compound [Mg+2].[Mg+2].[O-]P([O-])([O-])=O ILLRQJVNDWDWBA-UHFFFAOYSA-K 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- RGXWDWUGBIJHDO-UHFFFAOYSA-N ethyl decanoate Chemical compound CCCCCCCCCC(=O)OCC RGXWDWUGBIJHDO-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- DHNGCHLFKUPGPX-RMKNXTFCSA-N ethyl trans-p-methoxycinnamate Chemical compound CCOC(=O)\C=C\C1=CC=C(OC)C=C1 DHNGCHLFKUPGPX-RMKNXTFCSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- ZEACOKJOQLAYTD-UHFFFAOYSA-N flavan-3,3',4,4',5,5',7-heptol Chemical compound OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 ZEACOKJOQLAYTD-UHFFFAOYSA-N 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- XMHIUKTWLZUKEX-UHFFFAOYSA-N hexacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O XMHIUKTWLZUKEX-UHFFFAOYSA-N 0.000 description 2
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 238000000622 liquid--liquid extraction Methods 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- UTOPWMOLSKOLTQ-UHFFFAOYSA-N octacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O UTOPWMOLSKOLTQ-UHFFFAOYSA-N 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000010773 plant oil Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229940109850 royal jelly Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940005605 valeric acid Drugs 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 239000003357 wound healing promoting agent Substances 0.000 description 2
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- GYDYJUYZBRGMCC-INIZCTEOSA-N (2s)-2-amino-6-(dodecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCC(=O)NCCCC[C@H](N)C(O)=O GYDYJUYZBRGMCC-INIZCTEOSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZENZJGDPWWLORF-UHFFFAOYSA-N (Z)-9-Octadecenal Natural products CCCCCCCCC=CCCCCCCCC=O ZENZJGDPWWLORF-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-M 5-oxo-L-prolinate Chemical compound [O-]C(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-M 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- DJHGAFSJWGLOIV-UHFFFAOYSA-N Arsenic acid Chemical compound O[As](O)(O)=O DJHGAFSJWGLOIV-UHFFFAOYSA-N 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 229910052582 BN Inorganic materials 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 description 1
- 235000011960 Brassica ruvo Nutrition 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- OMPIYDSYGYKWSG-UHFFFAOYSA-N Citronensaeure-alpha-aethylester Natural products CCOC(=O)CC(O)(C(O)=O)CC(O)=O OMPIYDSYGYKWSG-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- KVSNMTUIMXZPLU-UHFFFAOYSA-N D:A-friedo-oleanane Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CCCC2C KVSNMTUIMXZPLU-UHFFFAOYSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920000043 Gallagic acid Polymers 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 235000017879 Nasturtium officinale Nutrition 0.000 description 1
- 240000005407 Nasturtium officinale Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241000183666 Nepsera aquatica Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241001529742 Rosmarinus Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 241000580955 Sapindus mukorossi Species 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 1
- 235000021322 Vaccenic acid Nutrition 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241001247821 Ziziphus Species 0.000 description 1
- GZQCZDHGTYFJIF-LZWOXQAQSA-N [(2r,3s,4s)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] acetate Chemical compound CC(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O GZQCZDHGTYFJIF-LZWOXQAQSA-N 0.000 description 1
- HEUMNKZPHGRBKR-UHFFFAOYSA-N [Na].[Cr] Chemical compound [Na].[Cr] HEUMNKZPHGRBKR-UHFFFAOYSA-N 0.000 description 1
- RJDOZRNNYVAULJ-UHFFFAOYSA-L [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[F-].[F-].[Mg++].[Mg++].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[K+] Chemical compound [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[F-].[F-].[Mg++].[Mg++].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[K+] RJDOZRNNYVAULJ-UHFFFAOYSA-L 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 244000193174 agave Species 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N alpha-methyl toluene Natural products CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940000488 arsenic acid Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- KYHMRXXFJAZYRF-MSBRYPFUSA-N benulin Chemical compound C([C@@](OC1)(O)C(C)(C)[C@@H]2CC[C@@]34C)C[C@@]12[C@H]4CC[C@H]1[C@@]3(C)CC[C@@]2(C(O)=O)CC[C@@H](C(=C)C)[C@H]12 KYHMRXXFJAZYRF-MSBRYPFUSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- 239000003738 black carbon Substances 0.000 description 1
- 239000003918 blood extract Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- DGQLVPJVXFOQEV-NGOCYOHBSA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-NGOCYOHBSA-N 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 229940114118 carminic acid Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229960000729 cyclandelate Drugs 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229940012466 egg shell membrane Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940057975 ethyl citrate Drugs 0.000 description 1
- ZJXZSIYSNXKHEA-UHFFFAOYSA-N ethyl dihydrogen phosphate Chemical compound CCOP(O)(O)=O ZJXZSIYSNXKHEA-UHFFFAOYSA-N 0.000 description 1
- ZJXZSIYSNXKHEA-UHFFFAOYSA-L ethyl phosphate(2-) Chemical compound CCOP([O-])([O-])=O ZJXZSIYSNXKHEA-UHFFFAOYSA-L 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000000451 gelidium spp. gum Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000003248 hydroxytyrosol Nutrition 0.000 description 1
- 229940095066 hydroxytyrosol Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940102253 isopropanolamine Drugs 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- KYHMRXXFJAZYRF-UHFFFAOYSA-N lantabetulic acid Natural products CC12CCC3C(C)(C)C(OC4)(O)CCC43C2CCC2C1(C)CCC1(C(O)=O)CCC(C(=C)C)C21 KYHMRXXFJAZYRF-UHFFFAOYSA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 125000005645 linoleyl group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-M nonanoate Chemical compound CCCCCCCCC([O-])=O FBUKVWPVBMHYJY-UHFFFAOYSA-M 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229940100684 pentylamine Drugs 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 150000003227 pyridoxines Chemical class 0.000 description 1
- 229940071139 pyrrolidone carboxylate Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003287 riboflavins Chemical class 0.000 description 1
- 229930195322 rubellin Natural products 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229940119485 safflower extract Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- OOTXFYSZXCPMPG-DJRORNMDSA-N taraxastane Natural products C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@H](C)[C@@H](C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C OOTXFYSZXCPMPG-DJRORNMDSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 150000003544 thiamines Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- KCAQMNLFUZFYKH-UHFFFAOYSA-N trihydroxy(octadecoxy)silane Chemical compound CCCCCCCCCCCCCCCCCCO[Si](O)(O)O KCAQMNLFUZFYKH-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000004330 tyrosol Nutrition 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 235000013799 ultramarine blue Nutrition 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- KDSWDGKIENPKLB-QJDQKFITSA-N verbascoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)CCC=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O KDSWDGKIENPKLB-QJDQKFITSA-N 0.000 description 1
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000009538 yokuinin Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229940098697 zinc laurate Drugs 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GPYYEEJOMCKTPR-UHFFFAOYSA-L zinc;dodecanoate Chemical compound [Zn+2].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O GPYYEEJOMCKTPR-UHFFFAOYSA-L 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to an external preparation for skin, and more particularly to an external preparation for skin having a whitening effect and a whitening agent.
- melanin is activated by darkness, dark spots, and freckles on the skin due to irritation caused by exposure to ultraviolet rays from sunlight, abnormalities in hormones, or genetic factors.As a result, melanin pigments synthesized by the melanocyte are converted into skin. It is caused by abnormal deposition in the inside.
- whitening agents such as L-ascorbic acid or its derivatives, hydroquinone derivatives, glutathione, and colloid have been developed.
- these whitening agents have problems such as those that have only a weak function of inhibiting melanin production, those that are easily oxidized and unstable, and those that produce a peculiar off-odor or precipitation. When used alone in cosmetics, the whitening effect was not always sufficient. Therefore, the development of a whitening agent that is highly effective, has a safe and stable whitening effect, or has an effect of preventing spots and freckles is currently required.
- maslinic acid is a kind of oleanane-based triterpene, and is a compound having the structure represented by the structural formula 1. It is known to have an anti-inflammatory effect and an anti-histamine effect. In nature, it is known to be found in olive, hop, hawaii, pomegranate, foliage, sage, jujube, etc.
- erythrodiol is a kind of oleanean triterpene, It has a structure like that of Structural Formula 2, and it is known that it has an anti-inflammatory effect (Planta. Med. VOL. 61, No. 2, 182-185, 1995). In nature, it is known to be present in Olive, Sunflower, Kinsen, Arabic arabic, Kodoxy, Nagabaka Konoki.
- uvaol is a kind of ursan triterpene and has a structure as shown in Structural Formula 3. Its action has been shown to be anti-inflammatory (Planta. Med. VOL. 61, No. 2, 182-185, 1995), glycerophosphate dehydrogenase inhibitory activity (Japanese Unexamined Patent Publication No. 9-672
- betulinic acid is a kind of lupine triterpene and has a structure similar to that of Structural Formula 4. It has been reported to function as a carcinostatic, anti-inflammatory, and wound healing agent. 4 1 2 6 6 2 3) Alcohol absorption inhibitory action
- betulin is a kind of lupine triterpene and has a structure as shown in Structural Formula 5, and its action has been a bioprotein denaturation inhibitory action (Japanese Patent Application Laid-Open No. 9-67253), Glycerophosphate dehydrogenase inhibitory action (Japanese Patent Application Laid-Open No. Hei 9-67249), lipase inhibitory action (Japanese Patent Laid-open No. 10-2653228), liver disease preventive action (Japanese Patent Laid-open No. Hei 11-20992) 75) is known. In nature, it is known to be present in the bark of birch and the like.
- maslinic acid, erythrodiol, ebaol, vellic acid, veline and / or a physiologically acceptable salt thereof, or a derivative thereof have extremely excellent whitening effects such as stains and freckles. That, so far, Was not well known. Disclosure of the invention
- An object of the present invention is to provide a skin external preparation, a whitening agent, etc. having an excellent whitening effect, and a skin external preparation, a whitening agent, which has an excellent whitening effect and is highly safe for the skin. And so on.
- the present inventors screened olive plants and their extracts and purified products using whitening action as an index, and found that maslinic acid and / or its physiologically acceptable They have found that salt has an excellent whitening effect, and have completed the present invention.
- salt has an excellent whitening effect, and have completed the present invention.
- a specific substance having a pentacyclic triterpene had a whitening effect, thereby completing the present invention.
- the present invention relates to one or more selected from pentacyclic triterpenes, maslinic acid, erythrodiol, ebaol, benulinic acid, benulin, and a physiologically acceptable salt thereof, or a derivative thereof.
- a skin external preparation containing two or more preferably, one selected from maslinic acid, erythrodiol, benzoyl, bellic acid, bellin and a physiologically acceptable salt thereof, or a derivative thereof
- a skin external preparation containing two or more kinds as a whitening component and is selected from maslinic acid, erythrodiol, ebaol, vellic acid, vellin, and physiologically acceptable salts thereof, or derivatives thereof.
- the present invention also relates to an external preparation for skin containing maslinic acid and / or a physiologically acceptable salt thereof, and preferably to an external preparation for skin containing as a whitening component. Also good Preferably, maslinic acid and / or a physiologically acceptable salt thereof, and a medicinal agent selected from a whitening agent, an antioxidant, an anti-inflammatory agent, a cell activator, a UV inhibitor, a blood circulation promoter, and a humectant.
- the present invention relates to an external preparation for skin characterized by containing one or more kinds.
- one or more active ingredients selected from maslinic acid, erythrodiol, ebadiol, berlinic acid, berlin and their physiologically acceptable salts, or derivatives thereof are used as active ingredients.
- the present invention relates to a whitening agent, and further relates to a skin external preparation containing the whitening agent.
- maslinic acid, erythrodiol, ebadiol, veric acid, and ellin which are the objects of the present invention, are substances represented by the following structural formulas 1 to 5, respectively, and physiologically acceptable salts thereof.
- the kind of the salt is not particularly limited as long as it is usually used in cosmetics or pharmaceutical compositions.
- the derivative is a derivative that can be formed biochemically or artificially. In the present invention, the derivative is not particularly limited as long as it is a derivative that can be formed biochemically or artificially.
- the maslinic acid and / or a physiologically acceptable salt thereof contained in the external preparation for skin and the whitening agent of the present invention is obtained from olive, hops, balsam, pomegranate, cypress, sage, and jujube.
- it is obtained by subjecting a product obtained in an orifice plant and / or olive oil production process to an extraction treatment with water and / or an organic solvent, followed by concentration treatment and / or fractionation / purification treatment.
- it is
- the present invention also uses a compound selected from the group consisting of maslinic acid, erythrodiol, ebaol, benulinic acid, veline, a physiologically acceptable salt thereof and a derivative thereof as an external preparation for skin or a whitening agent. About the method.
- the present invention also relates to a melanin production-suppressing agent containing a compound selected from the group consisting of maslinic acid, erythrodiol, ebaol, vernic acid, vellin, physiologically acceptable salts thereof, and derivatives thereof.
- the present invention further comprises a compound selected from the group consisting of maslinic acid, erythrodiol, ebaol, verpulinic acid, bellin, a physiologically acceptable salt thereof and a derivative thereof. To prevent buckwheat or dullness.
- the present invention also provides a skin external preparation, a whitening agent or a melanin of a compound selected from the group consisting of maslinic acid, erythrodiol, ebaol, verpulinic acid, vellin, physiologically acceptable salts thereof and derivatives thereof. It relates to its use as a functional agent for inhibiting the formation of diene.
- the present invention also relates to a whitening agent raw material containing a compound selected from the group consisting of maslinic acid, erythrodiol, benzoyl, velic acid, vellin, physiologically acceptable salts thereof and derivatives thereof, and The use of the compound as a raw material for whitening agents.
- the present invention also relates to maslinic acid obtained by subjecting a product obtained in an olive plant and / or olive oil production process to an extraction treatment with water and / or an organic solvent, and then subjecting the product to a concentration treatment and / or a fractionation / purification treatment. Its physiologically acceptable salts and / or their derivatives,
- the present invention relates to a method for producing a skin external preparation containing maslinic acid, a physiologically acceptable salt thereof, and / or a derivative thereof.
- the present invention further provides a masulin obtained by subjecting a product obtained in an olive plant and / or olive oil production process to an extraction treatment with water and / or an organic solvent, followed by concentration treatment and / or fractionation / purification treatment.
- a masulin obtained by subjecting a product obtained in an olive plant and / or olive oil production process to an extraction treatment with water and / or an organic solvent, followed by concentration treatment and / or fractionation / purification treatment.
- the present invention relates to a method for producing a lotion.
- the present invention relates to one or more selected from pentacyclic triterpenes such as maslinic acid, erythrodiol, ebaol, berylic acid, berlin and a physiologically acceptable salt thereof, or a derivative thereof.
- pentacyclic triterpenes such as maslinic acid, erythrodiol, ebaol, berylic acid, berlin and a physiologically acceptable salt thereof, or a derivative thereof.
- a skin external preparation containing two or more kinds preferably, it is selected from maslinic acid, erythrodiol, ebadiol, benulinic acid, veline and a physiologically acceptable salt thereof, or a derivative thereof.
- the present invention relates to a skin external preparation containing one or more kinds as a whitening component.
- pentacyclic triterpenes such as maslinic acid, erythrodiol, ebaol, berylic acid, bellin, and their physiologically acceptable salts, or derivatives thereof, may be obtained from natural sources. Those obtained by chemical synthesis may be used, and those existing as reagents may be used, and there is no particular limitation. If obtained from natural plants, it is preferable in terms of safety and security. For example, since maslinic acid and / or a physiologically acceptable salt thereof can be suitably obtained from the product obtained in the orifice plant and / or the olive oil production process, maslinic acid and / or its physiologically acceptable salt can be obtained.
- a skin external preparation containing a pharmaceutically acceptable salt and a skin external preparation containing maslinic acid and / or a physiologically acceptable salt thereof as a whitening component are preferable.
- “olive” means a product obtained in an olive plant and / or an olive oil production process.
- pentacyclic triterpenes such as maslinic acid, erythrodiol, ebadiol, berlinic acid, berlin and their physiologically acceptable salts, or derivatives thereof are not particularly limited. It is preferable that the content is 0.0000 to 10% by mass.
- Physiologically acceptable salts are those found in certain pentacyclic triterpenes—derived from COOH, usually in cosmetics or pharmaceuticals. There is no particular limitation as long as it is used in the composition.
- a derivative is a derivative that can be formed biochemically or artificially. In the present invention, the derivative is not particularly limited as long as it is a derivative that can be formed biochemically or artificially.
- the pentacyclic triterpenes, maslinic acid, erythrodiol, ebadiol, benulinic acid, bellin, and their physiologically acceptable salts, or derivatives thereof, have an extremely excellent whitening effect.
- one of the methods for evaluating the whitening effect one of the methods for evaluating the whitening effect
- vitamin C magnesium phosphate which is known as a substance having an excellent whitening effect.
- Chilled bellin has a high melanin production inhibitory function (whitening effect) of about 5 to 50 times. That is, the skin external preparation and the whitening agent of the present invention contain a pentacyclic triterpene and a physiologically acceptable salt thereof, or a derivative thereof, so that it has a very strong melanin production inhibitory function. Can be enjoyed.
- maslinic acid erythrodiol, ebaol, verinic acid, berlin and their physiologically acceptable salts, or derivatives thereof
- a whitening agent as a medicinal agent
- One or more of antioxidants, anti-inflammatory agents, cell activators, ultraviolet inhibitors, blood circulation promoters, and moisturizers can be blended. can do.
- the present invention relates to one or two selected from pentacyclic triterpenes such as maslinic acid, erythrodiol, ebaol, benulinic acid, veline, and physiologically acceptable salts thereof, and derivatives thereof.
- pentacyclic triterpenes such as maslinic acid, erythrodiol, ebaol, benulinic acid, veline, and physiologically acceptable salts thereof, and derivatives thereof.
- the above relates to a whitening agent containing an active ingredient.
- the present invention relates to a whitening agent containing maslinic acid and / or a physiologically acceptable salt thereof as an active ingredient, as described above.
- whitening agents can be used directly to obtain a skin whitening effect on the skin, and can be used as a raw material for the above-mentioned external preparation for skin.
- maslinic acid, erythrocyte diol, ebaol, berulinic acid, berlin and their physiologically acceptable salts, or their derivatives, contained in the skin external preparation and whitening agent of the present invention are as described above.
- Power that can also be obtained from natural plants In particular, maslinic acid and / or its physiologically acceptable salts can be obtained from olives, hops, hearts, pomegranates, chickpeas, sage, jujubes, To obtain from olive oil, the product obtained in the olive oil plant and / or olive oil production process is used as a raw material, extracted with water and / or an organic solvent, and further concentrated and / or fractionated and purified. Thereby, it can be suitably obtained.
- the olive plant is one or two or more selected from olive fruits, seeds, pericarp, leaves, stems, buds, or dried, crushed, or defatted products thereof
- the product obtained from the olive oil production process is compressed residue, extraction residue, compressed oil, extracted oil, degummed oil residue, deoxidized oil residue, dark oil, waste decolorizer, deodorized scum ,
- One or more selected from squeezed juice, wastewater, and waste filter media is compressed residue, extraction residue, compressed oil, extracted oil, degummed oil residue, deoxidized oil residue, dark oil, waste decolorizer, deodorized scum ,
- the present invention relates to one or more selected from pentacyclic triterpenes such as maslinic acid, erythrodiol, ebaol, berylic acid, berlin and a physiologically acceptable salt thereof, or a derivative thereof.
- the present invention relates to a skin external preparation and a skin lightening agent containing two or more kinds.
- the pentacyclic triterpene is a kind of triterpene, and is a pentacyclic compound composed of six isoprene units and having 30 carbon atoms. Individually, but Also included are those that undergo rearrangement, oxidation, elimination, or alkylation in the biosynthesis process and have different carbon numbers.
- Pentacyclic triterpenes are generally classified by their skeleton. For example, oleanan triterpenes, ursan triterpenes, lupine triterpenes, hoban triterpenes, seratan triterpenes, friedelane triterpenes, taraxeran triterpenes, taraxastan triterpenes, multifloran triterpenes And germanican triterpenes.
- the present inventors have found that, among these, specific pentagonal triterpenes, namely, maslinic acid of oleanane triterpene, erythrodiol, ebaol of ursan triterpene, berylic acid of lupine triterpene, and berlin Have found that they have an excellent whitening effect such as a melanin production inhibitory function, and have completed the present invention.At the same time, they are pentaneous triterpenes whose skeleton is similar to these, and are oleanolic acid of an oleananan-based triterpene.
- a specific substance has the whitening effect of the present invention, and a whitening effect is obtained simply by resembling the substance having the whitening effect found in the present invention.
- Has no fruit For example, oleanolic acid and maslinic acid have very similar structures, but their whitening effects are incomparable.
- the present inventors have found a substance having a whitening effect that exists randomly.
- the present invention relates to maslinic acid, erythrodiol, ebaol, berlinic acid, berlin, a physiologically acceptable salt thereof, or a derivative thereof.
- the present invention relates to a skin external preparation and a whitening agent containing one or more kinds of active ingredients, and more preferably to a skin external preparation and a whitening agent having a whitening effect such as a melanin production inhibitory function.
- the physiologically acceptable salt is a salt derived from a carboxyl group of a specific pentacyclic triterpene acid (partial structure: —COOX; X is any cationic substance),
- a specific pentacyclic triterpene acid partial structure: —COOX; X is any cationic substance
- alkali metal salts such as sodium, potassium, and lithium
- alkali metals such as calcium, magnesium, potassium, and zinc.
- Earth metal salts ammonia, methylamine, dimethylamine, trimethylamine, ethylamine, getylamine, triethylamine, propylamine, butylamine, alkylamine salts such as tetrabutylamine, pentylamine, hexylamine, ethanolamine, diethanolamine, Triethanolamine, propano Alkanolamine salts such as luamine, dipropanolamine, isopropanolamine, diisopropanolamine, other organic amine salts such as piperazine and piperidine, and basic amino acids such as lysine, arginine, histidine and tributaphan. And salts such as salts.
- alkali metal salts alkylamine salts, alcohol amine salts, and basic amino acid salts are preferred.
- these salts are more water-soluble than the specific pentacyclic triterpenes from which they are derived, and therefore are particularly preferable in the present invention particularly when applied in an aqueous system.
- the derivative is a derivative that can be formed biochemically or artificially.
- the derivative is not particularly limited as long as it is a possible derivative.
- a derivative having an alcohol ester group, a fatty acid ester Derivatives having an alkoxy group, derivatives having an alkoxymethyl group, and glycosides.
- derivatives having an alcohol ester group, derivatives having a fatty acid ester group, derivatives having an alkoxy group, and derivatives having an alkoxymethyl group are particularly preferred in comparison with the specific pentacyclic triterpenes from which they are derived.
- glycosides are particularly preferable when applied in an oil system.Glycosides are more water-soluble than the specific pentacyclic triterpenes from which they are derived, Is particularly preferred when applied in aqueous systems.
- derivatives exist in nature and can be obtained by isolating them, or can be obtained by artificially forming them. Further, the derivative of the present invention may be derivatized again, and salts thereof can be used.
- the alcohol ester group indicates a functional group formed as a result of a general dehydration reaction between a carboxyl group and an alcohol (partial structure: —COOR; R represents an arbitrary hydrocarbon-based functional group). That is, the derivative having an alcohol ester group of the pentacyclic triterpene in the present invention particularly refers to a derivative that can be formed from the carboxyl group and the alcohol.
- the alcohol at this time there are no particular restrictions on the alcohol at this time, but for example, methanol, ethanol, n-propanol, isopropanol, aryl alcohol, n-butanol, sec-butanol, tert-butanol, ethylene glycol, trimethylsilyl Alcohol, triethylsilyl alcohol, phenol, benzyl alcohol, saccharides and the like.
- methanol, ethanol, n-propanol, isopropanol, aryl alcohol, n-butanol, sec-butanol, tert-butanol ethylene glycol
- trimethylsilyl Alcohol triethylsilyl alcohol
- phenol benzyl alcohol
- saccharides and the like ethylene glycol
- derivatives formed from ethanol, triethylsilyl alcohol, methanol, n-propanol, isopropanol, and trimethylsilyl alcohol are preferred.
- the fatty acid ester group indicates a functional group formed as a result of a general dehydration reaction between a hydroxyl group and a fatty acid (partial structure: —OCOR; R represents an arbitrary hydrocarbon-based functional group). That is, the derivative having a fatty acid ester group of the pentacyclic triterpene in the present invention is, in particular, a derivative that can be formed from the hydroxyl group and the fatty acid. Show.
- fatty acids there are no particular restrictions on the fatty acids at this time, but, for example, acetic acid, acetic anhydride, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, pivalic acid, caproic acid, caprylic acid, capric acid, pendecanoic acid , Lauric acid, myristic acid, norremitic acid, perimitraic acid, stearic acid, oleic acid, elaidic acid, vaccenic acid, linoleic acid, linoleic acid, linolenic acid, alinolenic acid, arachidic acid, arachidic acid
- Examples include chidonic acid, eicosapenic acid, behenic acid, docosahexaneic acid, lignoceric acid, cerotic acid, montanic acid, and melisic acid.
- acetic acid acetic anhydride, couproic acid, caprylic acid, coupuric acid, lauric acid, myristic acid, palmitic acid, norremyleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linoleic acid, Derivatives formed from linolenic acid, allinolenic acid, arachidic acid, arachidonic acid, eicosapenic acid, behenic acid, and docosahexaenoic acid are preferred.
- an alkoxy group refers to a functional group formed as a result of a dehydration reaction between a general hydroxyl group and an alcohol (partial structure: -OR; R represents an arbitrary hydrocarbon-based functional group). That is, the derivative having an alkoxy group of the pentacyclic triterpene in the present invention particularly refers to a derivative which can be formed from the hydroxyl group and the alcohol.
- the alcohol used at this time is not particularly limited.
- derivatives formed from ethanol, triethylsilyl alcohol, methanol, n-propanol, isopropanol, and trimethylsilyl alcohol are preferred.
- the alkoxymethyl group refers to a functional group formed as a result of a dehydration reaction between a general hydroxymethyl group and an alcohol (partial structure: —CH 2 O R; Represents a hydrocarbon functional group. ). That is, the derivative of the pentacyclic triterbene having an alkoxymethyl group in the present invention particularly refers to a derivative that can be formed from the hydroxymethyl group and an alcohol.
- alcohols used at this time for example, methanol, ethanol, n-propanol, isopropanol, aryl alcohol, n-butanol, sec-butanol, tert-butanol, ethylene glycol , Trimethylsilyl alcohol, triethylsilyl alcohol, phenol, benzyl alcohol, saccharides and the like. Of these, derivatives formed from ethanol, triethylsilyl alcohol, methanol, n-propanol, isopropanol, and trimethylsilyl alcohol are preferred.
- Glycosides in the present invention include, among the above derivatives having an alcohol ester group, derivatives having an alkoxy group, and derivatives having an alkoxymethyl group, in particular, carboxyl groups, hydroxyl groups, and hydroxy groups of pentacyclic triterpenes.
- a derivative that can be formed from a methyl group and a saccharide is shown (partial structure: —COOR, —OR, —CH 20; R represents any saccharide).
- the saccharide at this time is not particularly limited, and examples thereof include glucose, mannose, galactose, fructose, xylose, arabinose, fucose, rhamnose, glucosamine, galactosamine, and glucuronic acid.
- glycosides may be monosaccharides or oligosaccharides of various combinations of disaccharides or more. Among them, there is a force s which is usually present naturally and is known by a generic name of saponin. In the present invention, any of these may be used.
- the present invention relates to an external preparation for skin and a whitening agent containing maslinic acid, erythrodiol, ebaol, berlinic acid, berlin and their physiologically acceptable salts or their derivatives as active ingredients. is there.
- a whitening effect such as a melanin production inhibitory function. It means that it contains as much as possible.
- the amount that exerts its effect refers to maslinic acid, erythrodiol, ebaol, benulinic acid, benlin and physiologically acceptable salts thereof contained in the skin external preparation and whitening agent of the present invention.
- the amount of the derivative thereof is an amount having a skin whitening effect on the skin.
- maslinic acid and erythrodiol are one type of oleane-based triterpenes, and are substances already known to be present in various plants.
- maslinic acid, erythrodiol, their physiologically acceptable salts and / or their derivatives are used in the skin external preparation and whitening agent of the present invention, the origin of these substances is not limited, Any of natural products, artificially synthesized products, and commercial products can be used.
- Maslinic acid is a kind of oleanane-based triterpene, and is a compound having the structure represented by Structural Formula 1. It is known to have an anti-inflammatory effect and an antihistamine effect. In nature, it is known to be present in olive, pop, heart-shaped, pomegranate, chickpea, sage, jujube, etc.
- the origin of maslinic acid and its physiologically acceptable salts or their derivatives is not limited, and those obtained from nature or artificially synthesized Any of commercially available products can be used.
- natural products such as olive, pop, knuckle, pomegranate, chickpea, sage, and jujube are preferred.
- Examples include orifice plants cultivated as a raw material for oils and fats. Olive plants are steadily and continuously grown
- maslinic acid and / or a physiologically acceptable salt thereof are preferably contained in a high concentration. Also preferred are those obtained from the products obtained in the olive oil production process.
- the physiologically acceptable salts and derivatives of maslinic acid are the same as described above. That is, the physiologically acceptable salt is derived from —COOH in the structural formula 1, and the kind of the salt is not particularly limited as long as it is usually used in foods and drinks or pharmaceutical compositions. .
- the physiologically acceptable salt is derived from —COOH in the structural formula 1, and the kind of the salt is not particularly limited as long as it is usually used in foods and drinks or pharmaceutical compositions.
- a salt of maslinic acid sodium masphosphate, potassium masphosphate, ammonium masphosphate, dimethylammonium masphosphate, calcium masphosphate, magnesium maslinate and the like can be mentioned. Of these, sodium masphosphate and potassium masphosphate are preferred.
- maslinic acid derivative examples include, for example, methyl maslinic acid ester, maslinic acid ethyl ester, maslinic acid n-propyl ester, maslinic acid isopropyl ester, and maslinic acid n-butyl ester when any one of the derivatives is derivatized.
- D-Glucoviranosyl monomaslinic acid 2—0 —? — D—Galactobilano Sil monomaslinic acid, 2-0- D-glucuronoviranosyl-massic acid, and the like.
- ethyl masphosphate triethylsilyl mastellate
- 3-0-acetyl-maslinic acid 2-0-acetyl-maslinic acid
- 2-0 Triethylsilyl monomaslinic acid
- 3-0-stearoyl-massic acid 2- ⁇ -stearoyl-massic acid
- a derivative in which only one group has been derivatized has been described above, a derivative in which two or more groups of which position and type can be derived are naturally derivatized may be used.
- 2,3-0-diacetyl, 2,3-0-ditriethylsilyl, and 2,3-distearoyl of the preferred maslinic acid or the above-mentioned preferred maslinic acid ester are preferable.
- only glycosides are listed as monosaccharides, but naturally, disaccharides or more oligosaccharides selected from various sugars may be used.
- Erythrodiol is a kind of oleanane-based triterpene and has a structure similar to that of Structural formula 2. Its action has been anti-inflammatory (Planta. Med. VOL. 61, No. 2, 182- 185, 1995). In nature, it is known to be present in olive, sunflower, Kinsen power, gum arabic, kodoxitan, and nagasuba konoki. In the skin external preparation and the whitening agent of the present invention, the origin of erythrodiol or a derivative thereof is not limited, and any of those obtained from nature, artificially synthesized, and commercially available products can be used.
- those obtained from natural sources such as olive, sunflower, kinsen, gum arabic, kodoxitan, and nagaka konoki are preferred.
- olive is preferred, and specifically, those obtained from products obtained in the olive plant and / or olive oil production process.
- physiologically acceptable salts and derivatives of erythrodiol are the same as described above.
- the derivative is not limited to the following, but, for example, assuming that any one of the derivatives is a derivative, 3-0-acetyl-erythrodiol, 3-0-p-open-pi-erythrodiol, 3- 0—butyryl-erythrodiol, 3-0—valeryl-erythrodiol, 3-0—capryluerythrodiol, 3 -—— lauryl-erythrodiol, 3-0—myristyl-erythrodiol, 3-—palmityl-erythrodiol, 3-0 ⁇ Remi toluyl erythrodiol, 3-0 to Stearoyl erythrodiol, 3 to 0 to oleyl erythrodiol, 3-0 to Baxenyl erythrodiol, 3-0 to Linoleyl erythrodiol, 3 to ⁇ - Linolenyl-erythrodiol, 3-0—A
- D glucosecoviranosyl—erythrodiol
- 28—0— D—galactopyranosyl erythridine
- 3-0-acetyl-erythrodiol and 28-0-acetylerythrodiol are preferred.
- only one derivative has been derivatized. However, it is needless to say that two or more groups of which the derived position and type can be derived are derivatized. For example, 3,28-0-diacetyl-erythrodiol can be mentioned.
- glycosides are listed as monosaccharides, but of course, disaccharides or more oligosaccharides selected from various saccharides may be used.
- Baool is a kind of ursan triterpenes and is a substance known to be present in various plants.
- the physiologically acceptable salts and derivatives thereof are the same as described above.
- ebaol, a physiologically acceptable salt thereof, or a derivative thereof is used in the skin external preparation and whitening agent of the present invention, the origin of these substances is not limited, and those obtained from nature, Any of artificially synthesized products and commercially available products can be used, but it is preferable to use natural products.
- Avaol is a type of ursan triterpene and has a structure similar to that of Structural Formula 3. It has been reported to have an anti-inflammatory effect (Planta. Med. VOL. 61, No. 2, 182- 185, 1995) and glycerophosphate dehydrogenase inhibitory activity (Japanese Patent Application Laid-Open No. 9-672249). Naturally, olive, deer, sage, a It is known to be present in rubber rubs, ryupte, etc.
- the origin of ebaol or a derivative thereof is not limited, and any of natural products, artificially synthesized products, and commercial products can be used. Those obtained from nature, such as olive, beetle, sage, gum arabic and capute are preferred. Olives are particularly preferred, and specifically those obtained from products obtained in the olive plant and / or oil production process.
- the derivative is not limited to the following, but, for example, assuming that any one of the derivatives has a derivative, 3-0-acetyl-baobaol, 3-0-propionyl-baobal, 3-0 —Butyryl— ⁇ baol, 3-0—valeryl— ⁇ baol, 3—0 _force prill— ⁇ baoyl, 3—0—lauryl—baobal, 3— ⁇ —myristyl— ⁇ baol, 3—0—palmityl— ⁇ baol, 3-0—Palmi Torail-Baal, 3-0-Stearoyl Baobal, 3-0 -Baile, 3-0-Baxenl-Baol, 3-0-Linoleyl-Baal , 3-0-linolenyl-baobal, 3-0-arachidyl-l-baol, 3-0-arachidonyl-l-baol,
- D-glucuronoviranosyl-l-baol and the like D-glucuronoviranosyl-l-baol and the like. Of these, 3-0-acetyl-baol and 28-0-acetyl-baol are preferred.
- only one derivative is derivatized as a derivative, but it is needless to say that two or more derivatized possible positions and types of these derivatives may be derivatized. For example, 3, 28-0-diacetyl 10 baol.
- glycosides are listed as monosaccharides, but naturally, disaccharides or more oligosaccharides selected from various sugars may be used.
- Beperic acid and bellin are both lupine-based triterpenes. It is a substance known to be present in plants.
- the physiologically acceptable salts and derivatives thereof are the same as described above.
- vellic acid, vellin, their physiologically acceptable salts, or their derivatives in the skin external preparation and whitening agent of the present invention the origin of these substances is limited. Instead, natural products, artificially synthesized products, commercially available products and the like can be used, but natural products are preferably used.
- Betulinic acid is a kind of lupine triterpene and has a structure like Structural formula 4. It has been reported to function as a carcinostatic, anti-inflammatory, and wound healing agent. It is known that it has an action of suppressing alcohol absorption (Japanese Patent Application Laid-Open No. 7-53385), a function of promoting hair growth (Japanese Patent Application Laid-Open No. 9-157713), and the like. In nature, it is known that it is present in a free state in sempuri, cinnamon, grape skin, olive oil, and the like, and is present as a saponin in ixin ginseng, carrot, sugar beet, and the like.
- the origin of berylic acid, a physiologically acceptable salt thereof, or a derivative thereof is not limited, and may be obtained from nature or artificially synthesized. Any of these can be used, and commercially available ones are preferred. For example, those obtained from natural sources, such as sempuri, cinnamon, grape, olive, chinsenjin, ginseng and sugar beet are preferred. In particular, a product obtained from an olive is preferable, and specifically, a product obtained from a product obtained in an olive plant and / or olive oil production process is preferable.
- berylic acid its physiologically acceptable salts and derivatives are the same as described above.
- physiologically acceptable salts are not limited to the following, but include, for example, sodium perphosphate, potassium perphosphate, ammonium perphosphate, dimethylammonium perphosphate, calcium perphosphate, and perchelic acid.
- examples include magnesium. Of these, sodium perphosphate and potassium perphosphate are preferred.
- berylic acid for example, if any one part is derivatized, methyl berylate, ethyl berylate, n-propyl berylate, isopropyl berylate, isopropyl berylate, N-butyl ester, trimethylsilyl belate, triethylsilyl belate, mono-/-D-glucoviranosyl ester, mono-D-galactopyranosyl ester, 3--0- D-galactopyranosyl ester Acetyl-bellinic acid, 3-0—propionylruberic acid, 3- ⁇ —butyryl monobellinic acid, 3-0—valeryl monobellinic acid, 3-0—capryruberic acid, 3-0—lauryl Monobellitic acid, 3-0—Myristyl—Berulinic acid, 3-0—Palmityl Monobellinic acid, 3—0—Palmi Acid, 3- ⁇ - stearoyl
- berylic acid ethyl ester is preferred.
- only one derivative has been derivatized.
- two or more derivatizable positions and types of these derivatives may be derivatized.
- glycosides are listed as glycosides.
- disaccharides or more oligosaccharides selected from various saccharides may be used.
- Betulin is a kind of lupine triterpene and has a structure as shown in Structural Formula 5. It has been reported to function as a bioprotein denaturation inhibitory agent (Japanese Patent Application Laid-Open No.
- the derivative is not limited to the following.
- any one of the derivatives is inducted, 3-0-acetyl-bellin, 3-0-propionii-rubellin, 3-0- Butyryl Bellin, 3-0—Valeryl Bellin, 3—0—Caprylu Bellin, 3-0—Lauryl Bellin, 3-0—Myristil—Bellin, 3-0—No Remichil Bellin, 3-0—Palmi Toray Luberlin, 3-0—Stearoyl Luberlin, 3-0—Oreyl One Bellin, 3— ⁇ One Baxen Two Lumberin, 3-0—Linolei Rubellin, 3-0—Linolenyl 1-Bellin, 3-0—Arachidyl-Bellin, 3—1-Arachidonyl-Bellin, 3—0—Bell-Bellin, 28 ———— Acetyl-Bellin, 28—0—Propion Perrin, 2 8—0—Butile loupe Phosphorus
- 3-0-acetyl-berin and 28-0-acetyl-berin are preferred.
- only one derivative is derivatized as a derivative.
- two or more derivatizable derivatized positions and types may be derivatized.
- 3,28-0-diacetyl-berin is preferred.
- glycosides are listed as monosaccharides, but of course, disaccharides or more oligosaccharides selected from various saccharides may be used.
- maslinic acid, erythrodiol, ebaol, betulinic acid, beverin and / or a physiologically acceptable salt thereof, or a derivative thereof have a whitening effect, especially maslinic acid and / or Alternatively, it has been found that a physiologically acceptable salt thereof or a derivative thereof has an extremely excellent whitening effect.
- the whitening effect refers to an effect of improving or preventing skin darkening, spots, freckles, and dullness caused by various factors such as exposure to ultraviolet rays, changes in hormonal balance, and genetic programs.
- dark and dark skin, spots, freckles, and dullness are caused by irradiating UV rays or changing hormonal balance. Is stimulated, and the biosynthesized melanin pigment is deposited on the skin and is known to occur. Therefore, if the production of melanin can be suppressed, it is possible to prevent and improve skin darkness, spots, freckles and dullness.
- the whitening effect is, for example, an effect of making the skin transparent and beautiful, or an effect of maintaining beautiful skin with transparency, an effect of reducing dullness of the skin and increasing gloss and firmness, and skin due to sunburn.
- the evaluation of the whitening effect is performed as follows. First, as a primary evaluation, using a B-16 melanoma cell culture test system, a cell whitening test (melanin production inhibitory function test) and a cytotoxicity test were compared. did. As a secondary evaluation, the effectiveness of the whitening effect was evaluated using actually prepared cosmetics. Pentacyclic triterpenes, which had a strong melanogenesis inhibitory function in the primary evaluation of cells, have excellent effects in the secondary evaluation, and the correlation between the effects in the two evaluation methods It was similar.
- B- 16 melanoma cells are cells that have melanin-producing ability, and cells that have proliferated spontaneously in culture become black. If a substance that suppresses melanin production is present in the system during this growth, the cells are suppressed from blackening and relatively whitened. Therefore, the whitening effect can be compared based on the degree of whitening at the time of adding the sample to the degree of blackening in the case of the control. Some substances are toxic to B-16 melanoma cells. To assess this cytotoxicity, cell viability is compared between control and sample addition. From the cell whitening test and the cytotoxicity test, a substantial whitening effect can be evaluated.
- the evaluation of the melanin production inhibitory function was carried out by using the well-known whitening agent Biminin C magnesium phosphate instead of the sample preparation solution for the whitening degree of cells (positive control), and Evaluate by comparing with the whitening degree (control) obtained in the same manner without the addition of the sample.
- maslinic acid As a result of the primary evaluation of whitening in the cell culture system, the whitening effect of maslinic acid, erythritol, ebaol, verpulinic acid, bellin and / or its physiologically acceptable salts, or derivatives thereof, was evaluated. Very strong, for example, about 100 to 200 times for maslinic acid, about 100 to 200 times for maslinic acid salt, about 100 to 100 times for erythritol, 30 to 120 times, about 30 to 120 times for berylic acid, about 10 to 100 times for bellin, about 100 to 2 times for ethyl maslin ester, acetyl Approximately 50-150 times for acetylated maslinic acid, approx.
- the external preparation for skin and the whitening agent of the present invention contain a pentagonal triterpene and a physiologically acceptable salt thereof, or a derivative thereof, thereby exhibiting a very strong melanin production inhibitory function. It can be enjoyed.
- maslinic acid, arsenic acid, etc. adjusted to a concentration having a similar whitening effect Erythrodiol, Baioru, Bellinic acid, Bellin and / or its physiologically acceptable salts, or their derivatives have low cytotoxicity.
- External preparations and whitening agents can be provided. However, excessive amounts may adversely affect the skin, so it is necessary to use an appropriate amount for the desired whitening effect.
- the external preparation for skin of the present invention has an extremely excellent whitening effect.
- the topical skin preparation of the present invention may be used in the form of maslinic acid, erythrodiol, benzoyl, valeric acid, berlin and / or a physiologically acceptable salt thereof, or a derivative thereof. Since it has a strong melanin production inhibitory function, it can minimize the production of melanin pigments, so it can improve or prevent skin darkening, spots, freckles, and dullness, and has an excellent whitening effect.
- the whitening effect of the external preparation for skin it can be confirmed by evaluating the effectiveness of the whitening effect using actually prepared cosmetics. For example, one or two or more selected from maslinic acid, erythrodiol, ebadiol, benulinic acid, benline and their physiologically acceptable salts, or their derivatives of the present invention are actually blended. It can be evaluated by formulating various skin external preparations such as cream, lotion, milky lotion, etc., and conducting a sensory evaluation test with a female panel using the skin external preparations. In other words, a panel of 15 women in their 20s to 50s is applied to the skin for the prescribed external preparation for test skin, etc., twice daily, morning and night, for a plurality of weeks. The whitening effect of the application can be evaluated by obtaining three levels of sensory test results: effective, slightly effective, and ineffective for making skin spots, freckles, and dullness less noticeable.
- the skin external preparation of the present invention has a whitening effect equal to or higher than that of a case where arbutin, kojic acid, etc., which are excellent whitening agents, are added as comparative products. I do. That is, the skin external preparation has an excellent whitening effect.
- maslinic acid, erythrodiol, ebaol, veric acid, and berlin are fat-soluble, they can be suitably blended with oil-based or emulsified skin external preparations and whitening agents. Particularly, for use in cosmetics, since it is fat-soluble, it has good transdermal absorbability, and it can provide a whitening effect to the skin, which is preferable.
- maslinic acid, erythrodiol, ebaol, berrulinic acid, physiologically acceptable salts of berylin, and their derivatives are water-soluble depending on the type of salt or derivative, and therefore, are aqueous or emulsified. It can be suitably blended in a skin external preparation and a whitening agent such as a system by uniformly dissolving or dispersing and including them.
- cosmetics are commercialized in water-based or emulsified systems.In this case, maslinic acid, erythrodiol, ⁇ baol, benulinic acid, and veline should be replaced with their physiologically acceptable salts, if necessary. By doing so, it can be suitably blended.
- maslinic acid, erythrodiol, ebaol, berylic acid, berlin and / or its physiologically acceptable salts, or derivatives thereof can be added to extremely small amounts of skin external preparations and whitening agents.
- the whitening effect that is normally required can be obtained, which has the merit of cost, and the room for mixing other components in terms of the mixing ratio occurs, so that other functions can be further enhanced. Good.
- the present invention comprises one or more selected from maslinic acid, erythrodiol, benzoyl, benulinic acid, bellin and / or a physiologically acceptable salt thereof, or a derivative thereof.
- a new external preparation for skin An external preparation for skin containing one or two or more selected from an acid, erythrodiol, benzoyl, berylic acid, berlin and / or a physiologically acceptable salt thereof, or a derivative thereof as a whitening component .
- the external preparation for skin includes drugs, quasi-drugs, and cosmetics, and is used for the skin.
- the form of the external preparation for skin is not particularly limited, and examples thereof include skin care cosmetics such as milky lotions, creams, lotions, knocks, and cleaning agents, makeup cosmetics such as lipsticks and foundations, cosmetics for the scalp, and ointments. Drugs, dispersions, creams, and external preparations.
- the content of maslinic acid, erythrodiol, ebadiol, velic acid, velin and / or a physiologically acceptable salt thereof or a derivative thereof in the skin external preparation of the present invention is not particularly limited, but is preferably 0.00001 mass. % To 10% by mass, more preferably 0.0001% to 5% by mass, still more preferably 0.000001% to 3% by mass, still more preferably 0.0001 to 5% by mass, and even more preferably 0.001% to 5% by mass.
- the external preparation for skin of the present invention contains maslinic acid and / or a physiologically acceptable salt or a derivative thereof as an active ingredient, preferably 0.000001 to 10% by mass, more preferably 0.1% by mass.
- the content is preferably 0001 to 5% by mass, more preferably 0.001 to 5% by mass.
- erythrodiol and / or a physiologically acceptable salt thereof or a derivative thereof is contained as an active ingredient in the external preparation for skin of the present invention, it is preferably 0.0005 to 10% by mass, more preferably 0.1 to 10% by mass. It is preferably contained in an amount of from 0005 to 6% by mass, more preferably from 0.005 to 6% by mass.
- ⁇ baol and / or a physiologically acceptable salt thereof or a derivative thereof is contained as an active ingredient in the external preparation for skin of the present invention, preferably 0.0002 to 10% by mass, more preferably 0.000002% by mass.
- the content is preferably from 5.2 to 5.2% by mass, more preferably from 0.002 to 5.2% by mass.
- the external preparation for skin of the present invention contains as an active ingredient vellic acid and / or a physiologically acceptable salt thereof or a derivative thereof, preferably 0.0002 to 10% by mass, more preferably 0% by mass. 0002 to 5.2% by mass, more preferably 0.002 to 5.2% by mass.
- bellin and / or a physiologically acceptable salt thereof or a derivative thereof is contained as an active ingredient in the external preparation for skin of the present invention, preferably 0.0003 to 10% by mass, more preferably 0.0003 to 10% by mass.
- the content is preferably 5.5% by mass, more preferably 0.0003 to 5.5% by mass.
- the present invention provides an active ingredient comprising one or more selected from maslinic acid, erythrodiol, ebadiol, benulinic acid, veline and / or a physiologically acceptable salt thereof, or a derivative thereof.
- Whitening agent As described above, maslinic acid, erythrodiol, ebaol, verinic acid, berlin and / or a physiologically acceptable salt thereof, or a derivative thereof have an extremely excellent whitening effect. Whitening agents have a very good whitening effect.
- To be contained as an active ingredient means that it is contained to such an extent that the desired whitening effect can be obtained, and the content is not particularly limited, but maslinic acid, erythrodiol, ⁇ baol, benulinic acid, benlin And / or a physiologically acceptable salt thereof or a derivative thereof is preferably 0.001% by mass or more, more preferably 0.001% by mass, based on the total mass of the whitening agent of the present invention. 9999.99% by mass, more preferably 0.05% by mass to 99.9% by mass, still more preferably 0.1% by mass to 99.5% by mass, more preferably 0.05 to 99.99% by mass.
- the content is preferably 10 to 99.99% by mass. It is preferable that the content is within the above range, because it can suitably exert a whitening effect even when used alone or in the skin external preparation of the present invention.
- maslinic acid and / or a physiologically acceptable salt thereof or a derivative thereof is contained as an active ingredient in the whitening agent of the present invention, it is preferably 0.001% by mass or more, more preferably 0.001 to 1% by mass.
- the content is preferably 99.9% by mass, more preferably 0.05 to 99.99% by mass, still more preferably 0.1 to 99.99% by mass, and still more preferably 1 to 99.99% by mass.
- erythrodiol and / or a physiologically acceptable salt thereof or a derivative thereof is contained as an active ingredient in the whitening agent of the present invention, it is preferably 0.005% by mass or more, more preferably 0.0005 to 99. 99% by mass, more preferably 0.1 to 99.99% by mass, still more preferably 0.2 to 99.99% by mass, more preferably 2.5 to 99.99% by mass, more preferably 4.
- the content is preferably from 5 to 99.99% by mass, more preferably from 6.5 to 99.99% by mass, and even more preferably from 10 to 99.9% by mass.
- Baobal and / or a physiologically acceptable salt thereof or a derivative thereof is contained as an active ingredient in the whitening agent of the present invention, it is preferably 0.002% by mass or more, more preferably 0.0002 to 99.9. 9% by mass, more preferably from 0.06 to 99.99% by mass, more preferably from 0.12 to 99.99% by mass, from 1.5 to 99.99% by mass, more preferably from 3.5 to 99.99% by mass.
- the content is preferably 99% by mass, more preferably 5.5 to 99.99% by mass, and even more preferably 10 to 99.99% by mass.
- the content is preferably 0.002% by mass or more, more preferably 0.02 to 99.99% by mass, still more preferably 0.06 to 99.99% by mass, and further preferably 0. 12 to 99.99% by mass, more preferably 1.5 to 99.99% by mass, still more preferably 3.5 to 99.99% by mass, further preferably 5.5 to 99.99% by mass, More preferably, the content is preferably 10 to 99.99.
- bellin and / or a physiologically acceptable salt thereof or a derivative thereof is contained as an active ingredient in the whitening agent of the present invention, it is preferably at least 0.003% by mass, more preferably at least 0.003 to 99% by mass. 99% by mass, 0.07 to 99.99% by mass, more preferably 0.15 to 99.99% by mass, more preferably 2 to 99.99% by mass, and still more preferably 4 to 99.99% by mass. %, More preferably 6 to 99.99% by mass, and even more preferably 10 to 99.99% by mass.
- an external preparation for skin having a whitening effect can be obtained by containing the whitening agent.
- the content of the whitening agent contained in the external preparation for skin is not particularly limited, and can be adjusted according to the desired whitening effect as described above.
- maslinic acid erythrodiol, ebaol, benulinic acid, velin and Z or a physiologically acceptable salt thereof, or a derivative thereof as a raw material for a whitening agent
- a whitening agent preferably 0.1% by mass or more, Preferably 0.1 to 99.99% by mass, more preferably 1 to 99.99% by mass, more preferably 10 to 99.99% by mass, more preferably 30 to 99.99% by mass, and still more preferably 50 to 99% by mass.
- 99.99% by mass more preferably 70 to 99.99% by mass, 80 to 99.99% by mass, and even more preferably 90 to 99.99% by mass.
- a whitening agent containing one or more active ingredients selected from acid, berlin and / or a physiologically acceptable salt thereof, or derivatives thereof as an active ingredient improves skin darkness, spots, freckles, etc.
- it is intended for prevention and achieves this purpose when used directly on the skin.
- it can be used for whitening skin spots and the like caused by burns and the like, and the whitening agent can be used in combination with an external preparation for skin and the like.
- pentacyclic triterpenes can be obtained naturally by extracting from the plant described therein. That is, each plant can be extracted with water and / or an organic solvent, and the extract can be further subjected to solvent extraction, a method utilizing the difference in solubility with impurities, fractionated precipitation, recrystallization, ion exchange resin, Separation and purification can be performed by using a liquid chromatography method alone or in an appropriate combination, or by using repeatedly.
- maslinic acid and / or its physiologically acceptable salts can be extracted from olive plants with water and / or an organic solvent, and the extract is subjected to a solvent extraction method to determine the solubility difference with impurities. Separation and purification can be performed by using a method, a fractional precipitation method, a recrystallization method, an ion exchange resin method, a liquid chromatography method, or the like alone or in an appropriate combination, or by repeatedly using the method.
- Olive plants (Olea europaea L.) can be used regardless of the locality of production, such as domestic or European, edible or oiled.
- Maslinic acid and / or a physiologically acceptable salt thereof contained in the external preparation for skin and the whitening agent of the present invention can be obtained mainly from natural or olive plants, fruits or seeds. It can be obtained from its seed coat, leaves, stems and buds. In addition, it can be suitably obtained from these dried, pulverized, and degreased products.
- the defatted product can be made from olive oil residue generated during the edible oil refining process or extraction residue with hexane or the like.
- the lipid component contained in the olive plant or the defatted product may be a hydrocarbon such as pentane, hexane or heptane, a lower fatty acid alkyl ester such as ethyl acetate, or a known water-insoluble organic solvent such as getyl ether.
- a defatted material obtained by extraction and removal with one or more kinds and further repeating this washing treatment as necessary can also be suitably used.
- maslinic acid and / or a physiologically acceptable salt thereof contained in the external preparation for skin and the whitening agent of the present invention can be obtained. .
- Organic solvents used to obtain maslinic acid and / or a physiologically acceptable salt thereof contained in the external preparation for skin and the whitening agent of the present invention from an olive plant include a hydrophilic organic solvent and a ⁇ 3 ⁇ 4 ⁇ organic solvent. Either one may be used, but a hydrophilic organic solvent is preferred.
- hydrophilic organic solvents methyl alcohol, ethyl alcohol, glycerin, propylene glycol, alcohols such as 1,3-butylene glycol, acetone, tetrahydrofuran, acetonitrile, 1,4-dioxane, pyridin, Known organic solvents such as dimethyl sulfoxide, ⁇ , ⁇ -dimethylformamide, acetic acid and the like can be mentioned. Of these, alcohols such as methyl alcohol, ethyl alcohol, glycerin, propylene glycol, and 1,3-butylene glycol are preferred, and ethanol is particularly preferred.
- hydrophobic organic solvent examples include known organic solvents such as hexane, cyclohexane, carbon tetrachloride, chloroform, dichloromethane, 1,2-dichloroethane, getyl ether, ethyl acetate, benzene, and toluene. These organic solvents are used alone or in combination of two or more. can do.
- a hydrophilic organic solvent from the viewpoint of, for example, permeability to plant tissue, extraction efficiency, and the like, and it is preferable to use a hydrated hydrophilic organic solvent.
- Specific examples include alcohols such as methyl alcohol, ethyl alcohol, glycerin, propylene glycol, and 1,3-butylene glycol, organic solvents such as acetone, tetrahydrofuran, and acetonitrile, and water-containing solvents thereof.
- the extraction conditions are not particularly limited.
- the temperature is 5 to 95 ° C. (preferably 10 ° C. to 90 ° C., more preferably 15 ° C. to 85 ° C., even at room temperature.
- the pressure can be extracted at normal pressure, under pressure, under reduced pressure by suction, etc.
- the extraction efficiency can be improved.
- extraction can be carried out using a shaking extractor or an extractor equipped with a stirrer, etc.
- the extraction time is several minutes to several hours depending on other extraction conditions. However, it may be determined appropriately according to production conditions such as production equipment and yield.
- the solvent used for the extraction may preferably be used in an amount of 1 to 100 times (“mass / mass”; the same applies hereinafter), more preferably 1 to 20 times the amount of the raw material. From the viewpoint of safety to the skin, it is particularly preferable to extract with water, a water-containing lower alcohol, or an anhydrous lower alcohol.
- the lower alcohol content is at least 10% by mass. It is preferred to extract with Further, it is preferable to use a hydroalcohol having a lower alcohol content of 10% by mass to 95% by mass, Most preferably, a water-containing lower alcohol whose lower alcohol content is adjusted to 30% by mass to 95% by mass is preferable.
- the alcohol used in the present invention is a primary alcohol such as methyl alcohol, ethyl alcohol, 1-propanol, 1-butanol, a secondary alcohol such as 2-propanol, 2-butanol, and a 2-alcohol.
- Known solvents such as tertiary alcohols such as methyl-2-propanol, and liquid polyhydric alcohols such as ethylene glycol, propylene glycol, and 1,3-butylene glycol, and the like. These can be used in combination.
- the lower alcohol is a known alcohol having 1 to 4 carbon atoms, for example, the above-mentioned primary, secondary, tertiary, or liquid polyhydric alcohols. One or more of these are combined. Can be used.
- the maslinic acid of the present invention and / or a physiologically acceptable salt thereof can be obtained.
- the removal of the solvent and water can be performed by a known method such as distillation under reduced pressure, reduced pressure / vacuum drying, freeze drying, spray drying and the like.
- the solvent or water may be contained, and the state is not particularly limited.
- the extract from the defatted product is preferable because it does not contain oil-soluble components such as triglyceride sterol and tocopherol, and it is not necessary to remove and purify these components.
- defatted matter is a very effective method of utilizing olive oil, because it can use pressed and extracted cakes obtained by pressing olive oil since it contains residues after oiling. It is an excellent method from the viewpoint of production cost because it uses the materials used for the production.
- maslinic acid and / or its physiologically acceptable salt extracted from olive plants maslinic acid and / or its physiologically acceptable salt extracted from olive plants, maslinic acid and / or its physiologic content contained in the external preparation for skin of the present invention, etc. Concentrate the salt acceptable to Preferably.
- the concentration conditions are not particularly limited, and examples thereof include a method using solubility in water.
- Maslinic acid and / or its physiologically acceptable salt contained in the external preparation for skin and the whitening agent of the present invention is a compound having relatively low polarity and poor water solubility. Utilizing this property, crude extracts from olive plants are divided into components that are hardly soluble in water and / or components that do not dissolve in water, that is, components that are poorly water-soluble and those that are easily soluble in water. By doing so, it can be significantly concentrated. Ingredients such as poor water solubility contained in crude extracts from olive plants are significantly superior in whitening effect even when compared to whole crude extracts from olive plants, and maslinic acid and / or its physiologically acceptable properties It can be confirmed that the salt is concentrated.
- Components having poor water solubility and the like can be easily obtained by adding a crude extract from an olive plant to water, stirring, and collecting a precipitated portion by filtration or the like.
- maslinic acid and / or its physiologically acceptable salt contained in the external preparation for skin of the present invention can be concentrated by liquid-liquid distribution using a common combination of solvents, if necessary. it can. Solvent combinations are generally difficult to specify, for example, water
- organic solvents in combination examples include hexane, carbon tetrachloride, chloroform, dichloromethane, 1,2-dichloroethane, getyl ether, ethyl acetate, n-butanol, Known organic solvents such as benzene and toluene are exemplified.
- maslinic acid and / or its physiologically acceptable salts are poorly water-soluble, unnecessary water-soluble components can be removed by separating the sfok-based organic solvent phase. By removing the solvent, maslinic acid and / or its physiologically acceptable salt can be easily concentrated.
- maslinic acid and / or a physiologically acceptable salt thereof contained in the external preparation for skin and the whitening agent of the present invention can be separated from the above-mentioned extract and / or concentrate. It is preferable to carry out a purification treatment. As a result, the concentration can be more than the above concentration, and the target component can be isolated.
- the advantages of the fractionation / purification treatment include not only that the whitening effect can be greatly improved, but also that impurities can be removed. That is, maslinic acid and / or a physiologically acceptable salt thereof can be obtained as white crystals when the fractionation and purification treatment is performed, so that an external preparation for skin and the like is not colored extra. It is advantageous because it has the advantage of being able to be suitably blended.
- the method of fractionation / purification is difficult to specify in general, but examples include recrystallization method, fractional precipitation method, and method using chromatography.
- the method utilizing liquid chromatography can be used without decomposing maslinic acid and / or a physiologically acceptable salt thereof contained in the external preparation for skin and the whitening agent of the present invention. It is preferable because it can be fractionated and purified well.
- Specific examples of liquid chromatography include normal-phase liquid chromatography, reversed-phase liquid chromatography, thin-layer chromatography, paper chromatography, and high-performance liquid chromatography (HPLC). Either method can be used for fractionating and purifying maslinic acid and / or a physiologically acceptable salt thereof contained in the external preparation for skin and the whitening agent of the present invention.
- normal phase liquid chromatography, reverse phase liquid chromatography, and high performance liquid chromatography (HPLC) are preferred, taking into account the resolution, throughput, and number of steps.
- normal phase liquid chromatography refers to, for example, the following method. That is, for example, a column was prepared using silica gel as the stationary phase, a mixture of hexane-monoethyl acetate and a mixture of chloroform and methanol, and the crude extract from the olive plant or a concentrate thereof was used at a load factor of 0. i-5% (wt (mass) / v am)), continuous elution with a single mobile phase or stepwise increase of solvent polarity This is a method in which a predetermined fraction is eluted by an elution method.
- Reverse phase liquid chromatography refers to, for example, the following method. That is, a column was prepared using silica (ODS) to which octane decylsilane was bonded as a stationary phase, a mixture of water and methanol, a mixture of water and acetonitrile, and a mixture of water and acetone, for example.
- ODS silica
- Crude plant extract or its concentrate at a load factor of 0.1 to 5% (wt (mass) / v) and continuous elution with a single solvent or stepwise elution with successively decreasing solvent polarity This is a method in which a predetermined fraction is eluted by the method.
- HPLC High performance liquid chromatography
- maslinic acid and / or its physiologically acceptable salt can be very concentrated and can be obtained in a state where impurities have been removed.
- the purity of maslinic acid and / or its physiologically acceptable salt can be adjusted by combining one or more of the above methods, and the strength and properties of the whitening effect as required Can also be designed.
- concentration treatment described above can be preferably repeated, and further, different concentration treatments can be combined.
- fractionation / purification process can be preferably performed repeatedly, and further, different fractionation / purification processes can be combined.
- fractionation and purification may be performed after concentration, or fractionation and purification may be performed after fractionation and purification, and fractionation and purification may be performed after concentration.
- a concentration treatment can be performed. Of course, combinations other than the above-mentioned combinations may be used.
- maslinic acid and / or a physiologically acceptable salt thereof can be suitably obtained.
- the combination is not particularly limited, but specific examples of the series of processing include the following methods.
- the hydrophilic organic solvent is removed from the obtained extract, and water-insoluble components precipitated in the aqueous layer are recovered.
- the precipitated water-insoluble matter can be recovered by filtration, centrifugation, or the like.
- water can be added to the aqueous solution, and treatment such as stirring can be performed as necessary.
- the extract in the dry state obtained by removing water and / or the hydrophilic organic solvent from the extract obtained from the orifice plant is subjected to treatment such as addition of water and stirring in the same manner as described above, followed by filtration and the like.
- the concentration treatment can be performed by collecting the water-insoluble matter. According to this concentration method, since the treatment is performed in an aqueous system, it is preferable because it is more safe than concentration using a solvent, and a wide range of equipment can be used. Also, since it contains almost no oil, it is also excellent in the efficiency of concentration and refining, which is preferable.
- the hydrophilic organic solvent is removed from the extract obtained from the olive plant, water is added to the remaining aqueous solution as needed, and a hydrophobic organic solvent is further added, whereby water-hydrophobic organic solvent is added.
- Concentration can be performed by liquid-liquid distribution with a solvent.
- the extract in a dry state can be concentrated by adding water and adding a hydrophobic organic solvent in the same manner as described above, whereby liquid-liquid partitioning with a water-hydrophobic organic solvent can be performed. it can. By fractionating and concentrating these concentrates by normal and / or reverse phase chromatography and / or recrystallization, highly purified maslinic acid and / or its physiologically acceptable Salt can be obtained.
- transdermal absorption is improved, the effects of impurities are eliminated, and colorless to pale and / or odorless to almost odorless It is preferable because it becomes a state.
- maslinic acid in a mixture of maslinic acid obtained from olive plant and / or a product obtained in the process of producing olive oil and a physiologically acceptable salt thereof and a physiologically acceptable maslinic acid and a salt thereof is preferably 95% or more, more preferably 95% to 99.99%. The content can be measured by, for example, gas chromatography.
- the external preparation for skin and the whitening agent of the present invention contain maslinic acid and / or a physiologically acceptable salt thereof.
- the external preparation for skin and the like of the present invention can also be obtained by containing the extract and the concentrate. You can also.
- the concentration of maslinic acid and / or its physiologically acceptable salt can be adjusted, and the maslinic acid and / or its physiologically acceptable salt can be suitably blended into a skin external preparation or the like. .
- a stronger effect is required, it can be concentrated, and when a weaker effect is sufficient, it can be diluted, so that a form suitable for use at a concentration suitable for the purpose of use can be obtained.
- the whitening effect can be designed by appropriately adjusting the strength and effect of the whitening effect.
- the strength of the whitening effect can be adjusted by, for example, concentrating when a stronger effect is required, and diluting and blending when a weaker effect is sufficient.
- the strength of the whitening effect can also be adjusted by combining maslinic acid with another whitening component other than the present invention such as maslinic acid.
- the effect of the whitening effect includes prevention of sunburn by cutting off ultraviolet rays, prevention of pigmentation occurring after sunburn, and improvement effect after pigmentation occurs. Such effects can be adjusted by combining other whitening agents other than the present invention with maslinic acid and the like.
- olive oil contains maslinic acid
- the use of olive oil as an oil component for the external preparation for skin and the whitening agent of the present invention is preferred because a more suitable whitening effect and the like can be obtained.
- a water-soluble composition containing oil when extracting from oil-containing fruit, a water-soluble composition containing oil can be obtained.
- the oil-containing water-soluble composition extracted from the oil-containing fruit has an advantage that it can be suitably used when the target product requires an oil, and the oil-containing water-soluble composition has an orifice of 100%. It is a composition having a whitening effect.
- oleic oil contains maslinic acid, it is preferable to use this composition for the external preparation for skin of the present invention.
- an emulsified composition of 100% of olive can be obtained, and this can be blended into an external preparation for skin and a whitening agent.
- the emulsified composition can be suitably blended or used as a base for blending other substances. .
- the emulsified composition consists of only an orifice, it is naturally derived and gives a sense of security as compared with a synthetic product. In addition, since the image of olive is good, it gives the user a better impression and security.
- this method is also a preferable method from the viewpoint of effective utilization of the entire olive.
- the above-mentioned emulsifiers include nonionic emulsifiers such as glyceryl monostearate, polyoxyethylene (POE) sorbitol fatty acid ester, polyoxyethylene (POE) sorbite fatty acid ester, sorbitan fatty acid ester, POE alkyl ether, POE 'Polyoxypropylene (POP) block polymer, P ⁇ E hardened castor oil ester and the like.
- Anionic emulsifiers include fatty acid soap, sodium alkyl sulfate and the like.
- the skin external preparation and the whitening agent of the present invention may contain other medicinal agents and the like.
- specific examples of the medicinal agent include the following.
- Other whitening agents other than the present invention include biyumin C and its derivatives and salts thereof, arbutin, gluyuthione, placenta extract, snowy evening extract, yokuinin extract, ogugon extract, and seaweed. Extract, wheat extract and the like.
- vitamin C and its derivatives and salts thereof particularly preferred are vitamin C and its derivatives and salts thereof, arbutin, glucanthione, and placenta extract.
- Antioxidants include enzymes such as superoxide dismutase, lipase, glutathioneperoxidase, tocopherol and its derivatives, dibutylhydroxytoluene, butylhydroxyanisole, and carotene.
- Carotenoids and derivatives thereof tannins such as gallagic acid ellagic acid and derivatives thereof, flavonoids such as flavone, catechin, quercetin, leucoanthocyanidin, quinones such as ubiquinone and vitamin K, Thiamines and salts thereof, riboflavins such as riboflavin and riboflavin acetate, pyridoxines such as pyridoxine hydrochloride and pyridoxine dioxynoate, nicotinic acids such as nicotinic acid amide and benzyl nicotinate, pyrilvin, mannitol, and tryptophan , Histidine, Le dihydro Guay ⁇ retinoic acid.
- flavonoids such as flavone, catechin, quercetin, leucoanthocyanidin
- quinones such as ubiquinone and vitamin K
- Thiamines and salts thereof riboflavins such as ribofla
- antioxidants particularly preferred are superoxide disperse, tocoprol and its derivatives, quercetin, mannitol and the like.
- Anti-inflammatory drugs include glycyrrhizic acid, glycyrrhetinic acid, allantoin, azulene, mefenamic acid, fenburubesone, indomethacin, ibuprofen, ketoprofen, aminocaproic acid, hydrocortisone, panthenol and Derivatives thereof, salts thereof, zinc oxide, diclofenac sodium, aloe extract, perilla extract, mugwort extract, potato extract, comfrey extract, jujube extract, watercress extract, etc. .
- anti-inflammatory agents particularly preferred are glycyrrhizic acid, glycyrrhetinic acid and derivatives thereof, and salts thereof.
- cell activators include royal jelly, photosensitizer, cholesterol and its derivatives, calf blood extract, vitamin A and its derivatives, citric acid, lactic acid, tartaric acid, lingoic acid, glycolic acid, succinic acid, serine, and glutamic acid. , Hydroxyproline, theanine, pyrrolidonecarboxylic acid, yeast extract, lactic acid bacteria extract, bifidobacterium extract, fermentation metabolism extract and the like.
- vitamin A and its derivatives particularly preferred are vitamin A and its derivatives, cunic acid, malic acid, lactic acid, serine, and pyrrolidonecarboxylic acid.
- UV inhibitors examples include benzoic acid-based UV absorbers such as para-aminobenzoic acid, anthranilic acid-based UV absorbers such as methyl anthranilate, salicylic acid-based UV absorbers such as methyl salicylate, and ethyl methacrylate.
- Benzophenone ultraviolet absorbers such as 2-hydroxy-14-methoxybenzophenone, etc.
- perocannic acid-based ultraviolet absorbers such as ethyl decanoate, 4-tert-butyl-4,1-medium
- Examples include toxicdibenzoylmethane, 2- (2-hydroxy-5,1-methylphenyl) benzotriazole, oxybenzone, titanium oxide, fine particles of titanium oxide, and zinc oxide.
- UV inhibitors particularly preferred are paramethoxy cake ethyl citrate, titanium oxide, fine particle titanium oxide, zinc oxide and the like.
- blood circulation promoters examples include assembly extract, cepharanthin, tocopherol and its derivatives, nicotinic acid and its derivatives, nonylate perenylamide, and capsaicy.
- Enzymes such as gingerone, gingerone, cantaris tincture, Ikuyu Mall, caffeine, tannic acid, hi-borneol, cyclandelate, cinnarizine, trazoline, acetylcholine, verapamil, a-orizanol, camphor, hinokitiol, lipase and papain , chili pepper extract, sempuri extract, aruni power extract, safflower extract, corn extract and the like.
- cepharanthin particularly preferred are cepharanthin, tocopherol and its derivatives, and oryzanol.
- humectant examples include polyhydric alcohols such as glycerin, diglycerin, propylene glycol, dipropylene glycol, 1,3-butylene glycol, and polyethylene glycol; proteins such as collagen, elastin, and keratin; Decomposition products and salts thereof, amino acids such as glycine, aspartic acid, arginine and derivatives thereof, sorbitol, xylitol, erythritol, trehalose, inositol, glucose, sucrose and derivatives thereof, dextrin and derivatives thereof, honey Saccharides, such as D-panthenol and its derivatives, hyaluronic acid and its salts, mucopolysaccharides such as chondroitin sulfate, pyrrolidone carboxylate, urea, phospholipid, glycolipid, ceramide, and sodium lactate Etc.
- polyhydric alcohols such as glycerin, diglycerin
- proteins such as propylene glycol, collagen, elastin and keratin, hyaluronic acid and its salts, and mucopolysaccharides such as chondroitin sulfate.
- the compounding amount of the medicinal agent in the skin external preparation or whitening agent of the present invention varies depending on the kind of the medicinal agent, but is preferably in the following range. Within this range, maslinic acid, erythrodiol, ebaol, vellic acid, vellin and / or its physiologically acceptable salts, or their derivatives, may adversely affect the product. To achieve higher whitening and skin Can be.
- the amount of other whitening agents other than the present invention in the skin external preparation or the whitening agent of the present invention is preferably 0.0001 to 10%, more preferably 0.0001 to 5%.
- these whitening agents and the whitening agent of the present invention are preferably used in the range of 0: 100 to 99.99: 0.01 (mass ratio).
- the placenta extract and the plant extract are used as the extract, the dry solid content may be within this range. Within this range, a skin external preparation exhibiting superior whitening and skin effect and having a good feeling of use can be obtained.
- the combined amount of the antioxidant in the skin external preparation or whitening agent of the present invention is preferably in the range of 0.0001 to 5%, more preferably 0.0001 to 3%.
- the dry solid content may be within this range. Within this range, a better antioxidant effect is seen, preventing skin inflammation, darkening, and aging due to the production of lipid peroxide in the skin, as well as showing excellent whitening and beautiful skin effects.
- An external preparation for skin is obtained.
- the compounding amount of the anti-inflammatory agent in the skin external preparation or whitening agent of the present invention is preferably in the range of 0.0001 to 5%, and more preferably in the range of 0.0001 to 3%.
- the dry solid content may be within this range.
- an external preparation for skin that exhibits an excellent anti-inflammatory effect and also has excellent whitening and skin effect can be obtained.
- the amount of the cell activator in the skin external preparation or whitening agent of the present invention is preferably 0.000001 to 5%, more preferably 0.0001 to 3%.
- the dry solid content may be within this range. Within this range, a skin external preparation that exhibits a more excellent effect of improving skin roughness and that exhibits excellent whitening and skin beautiful effects can be obtained.
- the amount of the UV inhibitor in the skin external preparation or whitening agent of the present invention is preferably More preferably, it is in the range of 0.1 to 20%, more preferably 0.1 to 10%. Within this range, a skin external preparation that exhibits a more excellent ultraviolet ray preventing effect and also has excellent whitening and skin beautiful effects can be obtained.
- the blending amount of the blood circulation promoting agent in the skin external preparation or whitening agent of the present invention is preferably in the range of 0.1 to 10%, more preferably 0.01 to 20%. Within this range, a skin external preparation that exhibits a more excellent blood circulation promoting effect and also has an excellent whitening and skin beautiful effect can be obtained.
- the amount of the humectant in the skin external preparation or whitening agent of the present invention is preferably in the range of 0.001 to 70%, more preferably in the range of 0.1 to 20%. Within this range, a skin external preparation that exhibits a more excellent moisturizing effect and also has excellent whitening and skin-smoothing effects can be obtained.
- whitening agents antioxidants, anti-inflammatory agents, cell activators, ultraviolet inhibitors, blood circulation promoters and humectants can be used alone or in combination of two or more.
- the external preparation for skin of the present invention can be prepared by blending with various forms of bases known as normal external preparations for skin according to a conventional method.
- Examples of the formulation of the external preparation for skin are not particularly limited, and examples thereof include cosmetics such as emulsions, creams, lotions, knocks, foundations, powders, detergents, makeup cosmetics, dispersions, and ointments. Drugs, topical drugs and quasi-drugs. Of these, emulsions, creams, lotions, tablets, foundations, and ointments are preferred.
- Examples of the formulation of the whitening agent of the present invention are not particularly limited.
- a milky lotion, a cream, a lotion, a knock, a foundation it can be used as cosmetics such as powders, detergents, makeup cosmetics, dispersions, ointments and the like, external medicines and quasi-drugs.
- cosmetics such as powders, detergents, makeup cosmetics, dispersions, ointments and the like, external medicines and quasi-drugs.
- emulsions, creams, lotions, knocks, foundations and ointments are preferred.
- whitening agent When used as a raw material to be incorporated into an external preparation for skin, there is no particular limitation as long as the necessary content can be obtained in the external preparation for skin, but, for example, a solid powder state, a solution state, a dispersion state, An emulsified state and the like can be mentioned, and any of them can be suitably used.
- the skin external preparation or the whitening agent of the present invention may contain, if necessary, a component usually used within a range that does not impair the effects of the present invention, that is, water (purified water, hot spring water, deep water, etc.). ), Oils, surfactants, metal soaps, gelling agents, powders, alcohols, water-soluble polymers, film-forming agents, resins, clathrates, antibacterials, fragrances, deodorants, salts, PH adjustment Agents, fresheners, extracts from plants, animals and microorganisms, astringents, antiseborrheic agents, chelating agents, keratolytic agents, enzymes, hormones, vitamins, etc. can be added.
- suitable components include those shown below.
- the “derivative” exemplified below includes a formable salt.
- the oil may be a natural oil, a synthetic oil, or an oil that is used in ordinary cosmetics to improve the constituent components of the base or to improve usability and usability.
- hydrocarbons such as liquid paraffin, squalane, petrolatum, olive oil, castor oil, jojoba oil, mink oil, madame nut nut oil, apricot kernel oil, persic oil, safflower oil, sunflower oil, avocado oil, meadow oil Oils of plant and animal origin, such as home oil, camellia oil, harmony oil, perilla oil, sesame oil, sesame oil, borage oil, cocoa butter, shea butter, lanolin, reduced lanolin, waxes such as beeswax, carnauba wax, candelilla wax, gay wax etc. And the like.
- liquid paraffin, squalane, beeswax, lanolin, and reduced lanolin are preferred.
- the compounding amount of the oil agent in the skin external preparation or whitening agent of the present invention is preferably from 0.01 to 90% by mass, more preferably from 0.1 to 50% by mass.
- Surfactants are used for emulsification and solubilization of oils and the like, and anionic, cationic, nonionic and amphoteric surfactants can be used.
- metal soap examples include metal salts other than alkali salts such as fatty acids, such as aluminum stearate, magnesium stearate, and zinc laurate.
- Gelling agents are used to stabilize the system, improve usability, and improve the feeling of use.
- Amino acid derivatives such as N-radioyl-L-glucamic acid; dextrin fatty acid esters such as dextrin palmitic acid ester; Sucrose fatty acid esters, organically modified clay minerals, and the like.
- Powders are used for a variety of purposes, mainly for coloring makeup cosmetics, concealing the skin, or improving the feeling of use. If the powder is used in ordinary cosmetics, its shape (spherical, needle-like, plate-like) Any of them can be used regardless of shape, particle size (fog-like, fine particles, pigment grade, etc.) and particle structure (porous, non-porous, etc.).
- inorganic powders include barium sulfate, calcium carbonate, talc, mica, synthetic mica, myriki, kaolin, sericite, caic acid, caic anhydride, aluminum magnesium silicate, ceramic powder, and boron nitride.
- Organic powders include polyester powder, polyethylene powder, polystyrene powder, nylon powder, lauroyl lysine, and the like.
- Colored pigments include iron oxide, black carbon black, sodium chromium, navy blue, Inorganic pigments such as ultramarine blue, tar-based pigments are raked, and natural pigments are raked.
- Pearl pigments include titanium oxide-coated mica, titanium oxide-coated myric, bismuth oxychloride, Titanium oxide coated oxy salted bismuth, titanium oxide coated talc, fish Foil, S varies titanium-coated colored mica, and other evening Ichiru dyes, natural pigments such as carminic acid. These powders may be compounded, or may be surface-treated with an oil agent, silicone, or a fluorine compound.
- alcohols examples include lower alcohols such as ethanol and isopropanol, and alcohols. Lyserin, diglycerin, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, polyethylene glycol and the like.
- the water-soluble polymer is used for stabilizing the system, improving usability and usability, and also for obtaining a moisturizing effect.
- Specific examples of the water-soluble polymer include plant-based polymers such as carrageenan, pectin, agar, and locust bean gum; microbial polymers such as xanthan gum; animal-based polymers such as casein and gelatin; and starches such as starch.
- Polymer methylcellulose, ethylcellulose, carboxymethylcellulose, cellulosic polymer such as hydroxypropylcellulose, nitrocellulose, crystalline cellulose, etc .; alginic acid polymer such as sodium alginate; vinyl such as carboxyvinyl polymer Polymers, polyoxyethylene polymers, polyoxyethylene polyoxypropylene copolymer polymers, acryl polymers such as sodium polyacrylate, and inorganic water-soluble polymers such as bentonite and hectrite Can be In addition, film-forming agents such as polyvinyl alcohol and polyvinyl pyrrolidone are also included in these. Of these, carboxyvinyl polymer, polyvinyl alcohol and carboxymethylcellulose are preferred.
- extracts derived from animals or microorganisms include serum deproteinized protein, egg components such as spleen and birds, eggshell membrane extract, cockscomb extract, shellfish extract, shellfish extract, royal jelly, silk protein and its degradation products, or their degradation products.
- an extract derived from animals or microorganisms By blending an extract derived from animals or microorganisms, a moisturizing effect, a cell activating effect, a whitening effect, an anti-inflammatory effect, a skin aging preventing effect, an active oxygen removing effect, a blood circulation promoting effect, and the like can be imparted.
- plant extraction site there are no particular restrictions on the plant extraction site, extraction method, etc., for plant extracts.
- the extraction solvent for example, one or more kinds of water; lower monovalent alcohols such as methyl alcohol and ethyl alcohol; and liquid polyhydric alcohols such as glycerin, propylene glycol and 1,3-butylene glycol may be used. it can.
- Extraction can also be carried out using a lipophilic solvent such as hexane, acetone, ethyl acetate, ether, etc.
- a lipophilic solvent such as hexane, acetone, ethyl acetate, ether, etc.
- extraction using an oily component such as squalane may be used.
- the resulting extract may be filtered, ion-exchanged, and adsorbed, decolorized and purified to form a solution, paste, gel, or powder.
- purification treatment such as deodorization and decolorization may be performed to the extent that the effect is not affected.
- Plants include Asparagus, Eiji, Raspberry, Kujin, Kaiketo, Gokahi, Coffee, Rice, Saishin, Hawthorn, Shirahuri, Peony, Tea, Beech, Mokko, Yukinoshi evening, Altea, Ashiba, Inchinko, Nettle, Obak, Otogirisou, King Gin Power, Salvia, Sikon, Birch, Mukuroji, Lenggeso, Omugi, Vietnamese Soup, Rosemary, Ouren, Grapefruit, Gentian, Svono, Shoub, Zio, Senkipo, Zenimapo, Zenimapo, Zenimapo , Bodaige, Maronier, Malmo mouth and the like.
- a moisturizing effect By blending the plant extract, a moisturizing effect, a cell activating effect, a whitening effect, an anti-inflammatory effect, a skin aging preventing effect, an active oxygen removing effect, a blood circulation promoting effect, and the like can be imparted.
- antibacterial agent examples include benzoic acid, sodium benzoate, paraoxybenzoic acid ester, parachloromethcresol, benzalkonium chloride, phenoxyethanol, and isopropylmethylphenol.
- saccharides such as lactose and glucose
- excipients such as dextrin, cellulose, citric acid (salt), calcium carbonate
- binders such as cellulose, starch, gelatin, saccharides, agar powder, gelatin powder, sodium alginate
- disintegrants such as cellulose derivatives and calcium carbonate. It can be prepared in liquid, solid, semi-solid, emulsified or mousse form.
- the external preparation for skin of the present invention can be produced according to a conventional method, and includes emulsions, creams, lotions, essences, cleansing, knocks, detergents, foundations, and the like, and other dispersions, granules, and ointments.
- Various external preparations for skin can be prepared.
- maslinic acid and / or a physiologically acceptable salt thereof are preferably obtained from an orifice, and thus may contain other components contained in the olive. .
- the other components contained in the orifice include, for example, triterpenes such as oleanolic acid and persolic acid, sterols such as sitosterol and campesterol, orleu mouth pane, verbascoside, rigast mouth side, tyrosol, hydroxytyrosol, May contain polyphenols such as rutin.
- triterpenes such as oleanolic acid and persolic acid
- sterols such as sitosterol and campesterol
- orleu mouth pane verbascoside
- rigast mouth side tyrosol
- hydroxytyrosol May contain polyphenols such as rutin.
- the above-mentioned components can be contained as needed, whereby the effects of the respective components can be enjoyed.
- the skin external preparation or whitening agent of the present invention containing maslinic acid, a physiologically acceptable salt thereof and / or a derivative thereof is obtained especially in an olive plant and / or olive oil production process.
- the product is extracted with water and Z or an organic solvent, and concentrated and / or fractionated / purified to obtain maslinic acid, a physiologically acceptable salt thereof, and / or a derivative thereof.
- the lotion of the present invention containing maslinic acid, a physiologically acceptable salt thereof and / or a derivative thereof can be obtained by converting the product obtained in the olive plant and / or olive oil production process into water and / or Alternatively, at least one alcohol is mixed with maslinic acid, a physiologically acceptable salt thereof, and / or a derivative thereof obtained by performing an extraction treatment with an organic solvent, followed by concentration treatment and / or fractionation / purification treatment. It can be manufactured by the following.
- the present invention relates to maslinic acid, erythrodiol, baioru, benulinic acid, berylin and the physiologically acceptable maslinic acid, erythrodiol, baioline, benulinic acid and the like which are similarly obtained from natural plants containing each pentacyclic triterpene.
- the present invention relates to a whitening agent containing one or more selected from salts thereof and one or two or more selected from derivatives thereof as an active ingredient, and further relates to an external preparation for skin containing the whitening agent.
- the external preparation for skin containing one or two or more selected from maslinic acid, erythrodiol, ebaol, benulinic acid, benline and / or a physiologically acceptable salt thereof, or a derivative thereof of the present invention is It has an extremely excellent whitening effect and is safe for the skin.
- maslinic acid is a highly safe component for the human body, since maslinic acid and Z or a physiologically acceptable salt thereof are naturally derived components obtained from Olive. Olives, which are widely used as food, are used as raw materials and can be obtained stably.
- the cosmetics used on a daily basis are mainly composed of natural ingredients that are safe for the skin, and that it can be said that actual users can use the cosmetics with peace of mind.
- the fact that the image is derived from a good olive plant is also preferable because it gives the user a spiritual exhilaration and a sense of security.
- erythrodiol (Funakoshi), Baol (Funakoshi), verpulinic acid (Funakoshi), and bellin (Funakoshi) were purchased as reagents. . Those of HPLC grade were used as they were, and those which were not were dissolved in ethanol heated to the boiling point until saturation, then cooled and recrystallized, filtered and dried. The maslinic acid will be described below with reference to examples, but the one extracted and purified from olive plants and confirmed to have a purity of 95% was used.
- this concentrate was fractionated by silica gel column chromatography using a column packed with about 40 times (400 g) of silica gel.
- the crude maslinic acid fraction was further purified by ⁇ DS column chromatography using a column packed with about 30 times (60 g) of octyl decylsilicone gel.
- vacuum drying was performed to obtain 1.5 lg of purified maslinic acid 1.
- the concentrate was fractionated by silica gel column chromatography using a column packed with about 40 times (500 g) of silica gel.
- the crude maslinic acid fraction was purified by ODS column chromatography using a column packed with about 30 times (80 g) of octadecyl silicic acid gel.
- maslinic acid 2.0 g was dissolved in 10 OmL of pyridine, 5 OmL of acetic anhydride was added, and the mixture was stirred overnight. After distilling off pyridine and acetic anhydride, the residue was dissolved in ether. The ether phase was washed once with a 1N aqueous hydrochloric acid solution, once with a saturated sodium hydrogen carbonate solution, and three times with pure water. In addition, it was left overnight. Magnesium sulfate was removed by filtration, and the crude reaction product obtained by evaporating the ether was purified by silica gel column chromatography to obtain 2.2 g of 2,3-0-diacetyl monomaslinic acid.
- maslinic acid 1.0 g was dissolved in 20 OmL of anhydrous dimethylformamide, and 144.Omg of imidazole and 350 / L of triethylsilyl chloride were added at 0 ° C, sealed, and stirred for 2 hours. After distilling off the dimethylformamide, the residue was dissolved in ether, and the ether phase was washed once with a 1N aqueous hydrochloric acid solution, once with a saturated sodium hydrogen carbonate solution, and three times with pure water, and then magnesium sulfate. Was added and left.
- the crude reaction product obtained by removing magnesium sulfate by filtration and distilling off the ether was purified by silica gel column chromatography, and 2,3-0-diethylethylsilyl-triethylsilyl maslinate was converted to 1 .5 g were obtained.
- erythrodiol 5.0 g was dissolved in 25 mL of pyridine, 100 mL of acetic anhydride was added, and the mixture was stirred overnight. After distilling off pyridine and acetic anhydride, the residue was dissolved in ether, and the ether phase was washed once with a 1N aqueous hydrochloric acid solution, once with a saturated sodium hydrogen carbonate solution and three times with pure water, and then washed with magnesium sulfate. Was added and left overnight.
- the magnesium sulfate was removed by filtration and the crude reaction product obtained by distilling off the ether was purified by silica gel column chromatography to obtain 5.4 g of 3,28-0-diacetylethylerythrodiol. Was.
- a 2 ml / we 11 medium was taken in a 6-well plate, a predetermined amount of B-16 melanoma cells were inoculated, incubated at 37 ° C and a carbon dioxide concentration of 5%, and cultured. The next day, a sample sample preparation solution was added and mixed to a predetermined concentration, and the culture was continued. The medium was changed on the fifth day of the culture, and the sample preparation solution was added again. The next day, remove the medium, collect the cells, and remove After washing with an acid-buffered saline), the cells were evaluated by the degree of whitening of the cells. The melanin production-suppressing effect was evaluated by using the well-known whitening agent Biyumin instead of the sample preparation.
- the evaluation criteria for the degree of whitening of the cells are as shown below.
- the cell viability is determined by the following formula at each addition concentration.
- Table 1 shows that the whitening effect of purified maslinic acid 1 and 2 shows the same degree of whitening when compared to the case where the additive concentration of magnesium phosphate magnesium vitamin C, which is a positive control, is 450 ppm.
- the whitening effect of the compounds of Synthesis Examples 1-4, which are derivatives of maslinic acid is the additive concentration that shows the same degree of whitening as the additive concentration of magnesium C phosphate magnesium, a positive control, at 450 ppm.
- Was 4 to 8 ppm which was found to have a skin whitening effect 56 to 11 times that of vitamin C magnesium phosphate.
- erythrodiol, ebaol, bellic acid, and bellin have the same degree of whitening when compared with the positive control, bismuthine C magnesium phosphate, at a concentration of 450 ppm.
- the indicated additive concentration was 10 to 25 ppm, indicating that the whitening effect was about 18 to 45 times that of bismuthine C magnesium phosphate.
- the addition concentration of the roll, Viminin C Magnesium Phosphate is about 10 to 25 ppm, which shows the same degree of whitening as 450 ppm, and is a whitening effect 18 to 45 times that of Magnesium Vitamin C. It was found to have
- the addition concentrations of erythrodiol, ebaol, berrulinic acid, and berlin which exhibit the same degree of whitening as the addition concentration of bebimin C magnesium phosphate of 450 ppm, are 10 to 25 ppm. Since the cell viability at the added concentration is 99% to 100%, when used as a skin lightening agent, erythrodiol, ebaol, bepulinic acid, and behline are combined with the existing whitening agent, vitamin C magnesium phosphate. The same level of safety was confirmed.
- Tables 1 and 2 show that the purified maslinic acid 1,2, erythrodiol, ⁇ baol, beculinic acid, and bentric acid of the present invention can be compared with arbutin ⁇ kojic acid, which is a widely used whitening agent. All of the compounds of the synthesis examples and the synthesis examples were excellent, and particularly, the whitening effect of purified maslinic acid 1 and 2 was extremely excellent. In addition, the cell viability at an added concentration of arbutin of 20 O ppm was 56%, and purified maslinic acid 1, 2, erythrodiol, ebaol, and bellin, which exhibited the same degree of whitening.
- maslinic acid, erythrodiol, ebaol, berlinic acid, berlin and / or a physiologically acceptable salt thereof, or a derivative thereof are known as vitamin C, which is widely used as an existing whitening agent. It was found to have a surprising whitening effect of about 18 to 110 times that of magnesium phosphate, especially 110 times for maslinic acid and / or its physiologically acceptable salts or derivatives thereof. . This has revealed that it is possible to provide a skin external preparation and a whitening agent having an extremely excellent whitening effect as never before.
- the creams of the present invention can prevent and improve the occurrence of dullness of the skin by applying them to the skin, resulting in beautiful skin.
- a lotion was prepared according to the following formulation and the following method.
- a and B were mixed and made uniform to obtain a lotion.
- An emulsion was prepared according to the following formulation and the following method.
- Components (9) to (13) are mixed by heating and kept at 70 ° C.
- a pack was prepared according to the following formulation and the following method.
- the above B was added to the above A, mixed, cooled, and (5) was uniformly dispersed to obtain a park.
- the pack of Formulation Example 4 has excellent stability over time, and when applied to the skin, it can regulate the texture of the skin, prevent dullness of the skin, and improve pigmentation such as spots, and have a clear feeling. It was a pack for beautiful skin.
- a liquid fashion was prepared according to the following formulation and the following production method.
- An emulsion for sunscreen was prepared according to the following formulation and the following method.
- a gel ointment was prepared according to the following formulation and the following method.
- the gel ointment of Formulation Example 7 has excellent stability over time, and by applying it to the skin, it can regulate the texture of the skin, prevent dullness of the skin, and improve pigmentation such as spots. It was intended to make the skin beautiful and rich.
- An emulsion was prepared according to the following formulation and the following production method.
- Components (9) to (13) are mixed by heating and kept at 70 ° C.
- the milky lotion of Formulation Example 8 has excellent stability over time, and when applied to the skin, it can prevent the occurrence of dullness on the skin and improve pigmentation such as spots, resulting in a beautiful, transparent skin. Was something.
- An emulsion for sunscreen was prepared according to the following formulation and the following method.
- a lotion was prepared according to the following formulation and the following method.
- the lotion of Formulation Example 10 has excellent stability over time, and when applied to the skin, it can prevent the occurrence of dullness on the skin and improve pigmentation such as spots, and has a clear feeling. It was for beautiful skin. According to the present invention, it is possible to provide a skin external preparation and a whitening agent having a strong whitening effect and low cytotoxicity.
- pentacyclic triterpenes such as maslinic acid, erythrodiol, ebaol, benulinic acid, veline and their physiologically acceptable salts, and derivatives thereof have an excellent whitening effect.
- a skin external preparation and a whitening agent having an excellent whitening effect can be provided.
- maslinic acid and / or a physiologically acceptable salt thereof can be obtained from plants such as olive, so that a whitening ingredient that is safe and has a very large whitening effect on the skin can be stably obtained, and Since it can be obtained from by-products of the oil pressing process, cost reduction can be expected.
- the pentacyclic triterpenes of the present invention have a slight and strong whitening effect It is expected to be applicable to products in the fields of cosmetics, pharmaceuticals, quasi-drugs, etc., and is expected to be suitably used for cosmetics because it has little effect on skin.
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01917726A EP1295587A1 (en) | 2000-03-31 | 2001-03-30 | External preparation for the skin and beautifying agents |
AU4468201A AU4468201A (en) | 2000-03-31 | 2001-03-30 | External preparation for the skin and beautifying agents |
CA002404012A CA2404012A1 (en) | 2000-03-31 | 2001-03-30 | External agent for the skin and whitening agent |
JP2001570227A JP3958968B2 (ja) | 2000-03-31 | 2001-03-30 | 皮膚外用剤及び美白剤 |
US10/259,323 US20030133958A1 (en) | 2000-03-31 | 2002-09-30 | External agent for the skin and whitening agent |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000097428 | 2000-03-31 | ||
JP2000-97428 | 2000-03-31 | ||
JP2000-258995 | 2000-08-29 | ||
JP2000258995 | 2000-08-29 | ||
JP2000-403353 | 2000-12-28 | ||
JP2000403353 | 2000-12-28 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/259,323 Continuation US20030133958A1 (en) | 2000-03-31 | 2002-09-30 | External agent for the skin and whitening agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001072265A1 true WO2001072265A1 (fr) | 2001-10-04 |
Family
ID=27342919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/002787 WO2001072265A1 (fr) | 2000-03-31 | 2001-03-30 | Preparation externe pour la peau et agents d'embellissement |
Country Status (8)
Country | Link |
---|---|
US (1) | US20030133958A1 (ja) |
EP (1) | EP1295587A1 (ja) |
JP (1) | JP3958968B2 (ja) |
KR (1) | KR20030005252A (ja) |
CN (1) | CN1427707A (ja) |
AU (1) | AU4468201A (ja) |
CA (1) | CA2404012A1 (ja) |
WO (1) | WO2001072265A1 (ja) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002043736A1 (fr) * | 2000-11-30 | 2002-06-06 | The Nisshin Oillio, Ltd. | Aliments et boissons embellissants et preparations perorales embellissantes |
JP2005082522A (ja) * | 2003-09-08 | 2005-03-31 | Kanebo Cosmetics Inc | 美白化粧料 |
JP2005179285A (ja) * | 2003-12-22 | 2005-07-07 | Lotte Co Ltd | ヒスタミン遊離抑制剤及びそれを含む飲食品 |
WO2005067885A1 (en) * | 2004-01-15 | 2005-07-28 | Amorepacific Corporation | Skin whitening composition having synergic whitening effect |
WO2006132033A1 (ja) * | 2005-06-10 | 2006-12-14 | Pola Chemical Industries Inc. | 新規トリテルペン酸誘導体及びそれを含有してなる皮膚外用剤 |
JP2007332066A (ja) * | 2006-06-14 | 2007-12-27 | Nikko Chemical Co Ltd | チロシナーゼ産生抑制剤 |
JP2007332088A (ja) * | 2006-06-16 | 2007-12-27 | Pola Chem Ind Inc | ベシクル系に好適な皮膚外用剤 |
JP2008074761A (ja) * | 2006-09-20 | 2008-04-03 | Naris Cosmetics Co Ltd | 化粧料 |
JP2009137846A (ja) * | 2007-12-04 | 2009-06-25 | Kyoei Kagaku Kogyo Kk | 化粧料 |
JP2009542632A (ja) * | 2006-07-04 | 2009-12-03 | ウォンキソファーム カンパニー リミテッド | 新規な環式化合物の誘導体及びその用途 |
JPWO2008018118A1 (ja) * | 2006-08-07 | 2009-12-24 | 株式会社ノエビア | ネマガリダケ含有組成物、保湿剤、細胞賦活剤、美白剤及び抗酸化剤 |
JP2010116350A (ja) * | 2008-11-13 | 2010-05-27 | Maruzen Pharmaceut Co Ltd | エンドセリン−1mRNA発現抑制剤、幹細胞増殖因子(SCF)mRNA発現抑制剤、塩基性線維芽細胞増殖因子(bFGF)mRNA発現抑制剤、及びプロオピオメラノコルチン(POMC)mRNA発現抑制剤 |
JP2011236150A (ja) * | 2010-05-10 | 2011-11-24 | Nippon Flour Mills Co Ltd | マスリン酸を有効成分とする抗アレルギー剤 |
CN102552969A (zh) * | 2011-12-21 | 2012-07-11 | 深圳市宜丽环保科技有限公司 | 一种具有抑菌及美白功能的卫生护垫 |
JP2013010715A (ja) * | 2011-06-29 | 2013-01-17 | Nippon Flour Mills Co Ltd | う蝕予防剤、歯周病予防剤及び口腔用組成物 |
WO2018066704A1 (ja) * | 2016-10-07 | 2018-04-12 | 国立大学法人 九州大学 | メラニン抑制剤、抗菌剤、抗アレルギー剤、コラーゲン生成促成剤および保湿剤 |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10035190C5 (de) | 2000-07-20 | 2009-07-16 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Verfahren und Vorrichtung zur Fluoreszenzmessung |
US20040115290A1 (en) | 2001-06-20 | 2004-06-17 | Tripp Matthew L. | Modulation of inflammation by hops fractions and derivatives |
US7901714B2 (en) * | 2001-06-20 | 2011-03-08 | Metaproteomics, Llp | Treatment modalities for autoimmune diseases |
US7901713B2 (en) * | 2001-06-20 | 2011-03-08 | Metaproteomics, Llc | Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops |
US8206753B2 (en) * | 2001-06-20 | 2012-06-26 | Metaproteomics, Llc | Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes |
US7718198B2 (en) * | 2001-06-20 | 2010-05-18 | Metaproteomics, Llc | Treatment modalities for autoimmune diseases |
US7666449B2 (en) * | 2001-06-20 | 2010-02-23 | Metaproteomics, Llc | Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity |
US8142819B2 (en) | 2002-10-21 | 2012-03-27 | Metaproteomics, Llc | Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response |
US7270835B2 (en) * | 2001-06-20 | 2007-09-18 | Metaproteomics, Llc | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
US8168234B2 (en) | 2001-06-20 | 2012-05-01 | Metaproteomics, Llc | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
US7205151B2 (en) * | 2001-06-20 | 2007-04-17 | Metaproteomics, Llc | Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
US8158160B2 (en) | 2001-11-13 | 2012-04-17 | Eric Hauser Kuhrts | Anti-inflammatory cyclooxygenase inhibitors |
MXPA05004288A (es) * | 2002-10-21 | 2005-08-02 | Metaproteomics Llc | Composiciones para tratar o inhibir los estados patologicos asociados con la respuesta inflamatoria. |
US6890566B2 (en) * | 2002-12-11 | 2005-05-10 | Desert Whale Jojoba Company | Composition and method to whiten and exfoliate skin |
MXPA05012584A (es) * | 2003-05-22 | 2006-05-25 | Metaproteomics Llc | Composiciones farmaceuticas anti-inflamatorias para disminuir la inflamacion, y tratamiento o prevencion de toxicidad gastrica. |
US6893488B2 (en) * | 2003-07-15 | 2005-05-17 | Armor Holdings Forensics, Inc. | Fingerprint compound and method |
US7914831B2 (en) * | 2004-02-27 | 2011-03-29 | Metaproteomics, Llc | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines |
US20050192356A1 (en) * | 2004-02-27 | 2005-09-01 | Babish John G. | Synergistic anti-inflammatory pharmaceutical compositions and methods of use |
ES2246711B1 (es) * | 2004-06-23 | 2007-11-01 | Provital, S.A. | Composicion dermocosmetica. |
EP2263663A1 (en) * | 2004-11-13 | 2010-12-22 | Metaproteomics, LLC | Compositions comprising curcuminoids and either alpha or beta acids for use in the treatment of diabetes |
KR100704003B1 (ko) * | 2005-06-10 | 2007-04-06 | 안동대학교 산학협력단 | 2-알파-하이드록시-올레아놀산을 함유하는 트롬빈 저해혈전증 예방 및 치료용 조성물 |
AU2006280074A1 (en) * | 2005-08-09 | 2007-02-22 | Metaproteomics, Llc | Protein kinase modulation by hops and acacia products |
CA2632684A1 (en) * | 2005-12-09 | 2007-06-14 | Metaproteomics, Llc | Protein kinase modulation by hops and acacia products |
FR2895677B1 (fr) * | 2006-01-05 | 2012-05-25 | Fabre Pierre Dermo Cosmetique | Utilisation d'un extrait insaponifiable de pulpe vegetale dans le traitement du vieillissement cutane. |
FR2895678B1 (fr) * | 2006-01-05 | 2008-08-15 | Oreal | Utilisation cosmetique d'un extrait de menthe |
TW200817027A (en) * | 2006-06-20 | 2008-04-16 | Metaproteomics Llc | Isoalpha acid based protein kinase modulation cancer treatment |
US20080051466A1 (en) * | 2006-06-20 | 2008-02-28 | Metaproteomics, Llc | Isoalpha acid based protein kinase modulation cancer treatment |
NZ579340A (en) * | 2007-03-19 | 2012-05-25 | Metaproteomics Llc | Methods and compositions for promoting bone and joint health comprising berberine |
ES2304322B1 (es) * | 2007-03-23 | 2009-08-13 | Universidad De Granada | Uso de acido maslinico y sus derivados para la inhibicion de elastasa y para el tratamiento de enfermedades y sintomatologias con ellas relacionadas. |
KR20100029201A (ko) * | 2007-05-11 | 2010-03-16 | 메타프로테오믹스, 엘엘씨 | 중금속 해독 방법 및 조성물 |
CN101969972A (zh) * | 2007-12-10 | 2011-02-09 | 麦特普罗泰欧米克斯有限公司 | 癌症、血管生成、以及与其相关的炎症通路的取代的1,3-环戊二酮多靶点蛋白激酶调节剂 |
KR20110010603A (ko) * | 2008-04-02 | 2011-02-01 | 메타프로테오믹스, 엘엘씨 | 치환된 1,3-시클로펜타디온 약독화 내피 염증 및 내피-모노사이트 상호작용 |
ES2328999B1 (es) | 2008-04-03 | 2010-10-27 | Biomaslinic S.L. | Uso del acido maslinico para el tratamiento de patologias y sus sintomas mediante la inhibicion de cox-2. |
US20120128609A1 (en) * | 2008-11-13 | 2012-05-24 | Sergio Amari | Cosmetic use of natural emulsifiers |
ATE510530T1 (de) * | 2009-02-17 | 2011-06-15 | Rahn Ag | Verfahren zur verhinderung und/oder behandlung von altersflecken |
DE102009047092A1 (de) * | 2009-11-24 | 2011-05-26 | Birken Gmbh | Verwendung eines triterpenhaltigen Oleogels zur Wundheilung |
JP2011157306A (ja) * | 2010-02-02 | 2011-08-18 | Fujifilm Corp | ポリフェノール含有量を低減させたサラシア抽出物 |
WO2013190542A2 (en) * | 2012-06-17 | 2013-12-27 | Kamedis Ltd | Topical compositions for the treatment of chronic inflammatory skin disease |
JP5768114B2 (ja) * | 2013-11-29 | 2015-08-26 | ポーラ化成工業株式会社 | エージング対応用の皮膚外用剤の製造方法 |
RU2554826C1 (ru) * | 2014-07-02 | 2015-06-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Забайкальский государственный университет" (ФГБОУ ВПО "ЗабГУ") | Биосредство для очистки и восстановления кожи |
BR102015003242B1 (pt) * | 2015-02-12 | 2020-07-28 | E.M.S.S.A | composição cosmética e uso da mesma |
KR101684432B1 (ko) * | 2015-06-12 | 2016-12-08 | 서울대학교 산학협력단 | 카테치노세아노틱산 화합물 및 이를 포함하는 약학적 조성물 |
CN106730012A (zh) * | 2017-02-08 | 2017-05-31 | 于晓兵 | 一种胶原基可降解脊柱融合器及其制备方法 |
JP6389308B1 (ja) * | 2017-08-23 | 2018-09-12 | 一丸ファルコス株式会社 | 皮膚外用剤 |
BR112020009867A2 (pt) | 2018-01-04 | 2020-11-03 | Amryt Research Limited | composição formadora de cremosidade |
ES2756898B2 (es) | 2018-10-26 | 2021-11-26 | E Grau Active Cosmetics S L U | Un concentrado a base de aceite de oliva y un preparado de aplicación tópica para el cuidado de la piel que comprende dicho concentrado |
KR102169239B1 (ko) | 2018-11-30 | 2020-10-23 | 이스트힐(주) | 마스린산 유도체를 포함하는 피부 주름 개선용 조성물 |
KR102068794B1 (ko) * | 2019-05-30 | 2020-01-22 | 주식회사 코씨드바이오팜 | 강아지풀 추출물을 유효 성분으로 함유하는 동물용 화장료 조성물 및 동물용 의약 조성물 |
KR102625163B1 (ko) * | 2020-12-01 | 2024-01-16 | 재단법인 경기도경제과학진흥원 | 물박달나무 추출물을 이용한 피부 주름 개선 및 피부 미백용 조성물 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5857307A (ja) * | 1981-09-30 | 1983-04-05 | Pola Chem Ind Inc | 化粧料 |
JPH07149622A (ja) * | 1993-09-07 | 1995-06-13 | Shiseido Co Ltd | 美白用製剤 |
EP0717983A1 (en) * | 1994-12-20 | 1996-06-26 | Unilever Plc | Cosmetic compositions containing betulinic acid |
JPH0967253A (ja) * | 1995-09-04 | 1997-03-11 | Lion Corp | 生体タンパク質変性抑制剤 |
JPH0987156A (ja) * | 1995-09-19 | 1997-03-31 | Pola Chem Ind Inc | 光老化防止剤及び皮膚化粧料 |
WO1998000093A1 (fr) * | 1996-07-02 | 1998-01-08 | Pola Chemical Industries Inc. | Inhibiteur du photo-vieillissement et preparation pour les soins de la peau |
JPH1025236A (ja) * | 1996-07-10 | 1998-01-27 | Pola Chem Ind Inc | 肌の不均一性改善増強剤及びそれを含有する化粧料 |
JPH10152444A (ja) * | 1996-11-22 | 1998-06-09 | Nippon Flour Mills Co Ltd | メイラード反応抑制剤及び化粧料 |
JPH10265328A (ja) * | 1997-03-27 | 1998-10-06 | Nippon Flour Mills Co Ltd | 化粧料、ペットフード、リパーゼ阻害剤及びそれを含む食品 |
JPH11292752A (ja) * | 1998-04-13 | 1999-10-26 | Lion Corp | 美白剤及び皮膚外用組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3458041B2 (ja) * | 1995-09-19 | 2003-10-20 | ポーラ化成工業株式会社 | 光老化防止剤及び皮膚化粧料 |
JP3993936B2 (ja) * | 1998-05-22 | 2007-10-17 | 一丸ファルコス株式会社 | メラニン生成抑制剤及び化粧料組成物 |
JP2001002550A (ja) * | 1999-06-18 | 2001-01-09 | Ichimaru Pharcos Co Ltd | オリーブ葉抽出物、皮膚外用剤又は浴用剤への応用 |
-
2001
- 2001-03-30 JP JP2001570227A patent/JP3958968B2/ja not_active Expired - Fee Related
- 2001-03-30 CA CA002404012A patent/CA2404012A1/en not_active Abandoned
- 2001-03-30 KR KR1020027013053A patent/KR20030005252A/ko not_active Application Discontinuation
- 2001-03-30 AU AU4468201A patent/AU4468201A/xx active Pending
- 2001-03-30 CN CN01808871A patent/CN1427707A/zh active Pending
- 2001-03-30 WO PCT/JP2001/002787 patent/WO2001072265A1/ja not_active Application Discontinuation
- 2001-03-30 EP EP01917726A patent/EP1295587A1/en not_active Withdrawn
-
2002
- 2002-09-30 US US10/259,323 patent/US20030133958A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5857307A (ja) * | 1981-09-30 | 1983-04-05 | Pola Chem Ind Inc | 化粧料 |
JPH07149622A (ja) * | 1993-09-07 | 1995-06-13 | Shiseido Co Ltd | 美白用製剤 |
EP0717983A1 (en) * | 1994-12-20 | 1996-06-26 | Unilever Plc | Cosmetic compositions containing betulinic acid |
JPH0967253A (ja) * | 1995-09-04 | 1997-03-11 | Lion Corp | 生体タンパク質変性抑制剤 |
JPH0987156A (ja) * | 1995-09-19 | 1997-03-31 | Pola Chem Ind Inc | 光老化防止剤及び皮膚化粧料 |
WO1998000093A1 (fr) * | 1996-07-02 | 1998-01-08 | Pola Chemical Industries Inc. | Inhibiteur du photo-vieillissement et preparation pour les soins de la peau |
JPH1025236A (ja) * | 1996-07-10 | 1998-01-27 | Pola Chem Ind Inc | 肌の不均一性改善増強剤及びそれを含有する化粧料 |
JPH10152444A (ja) * | 1996-11-22 | 1998-06-09 | Nippon Flour Mills Co Ltd | メイラード反応抑制剤及び化粧料 |
JPH10265328A (ja) * | 1997-03-27 | 1998-10-06 | Nippon Flour Mills Co Ltd | 化粧料、ペットフード、リパーゼ阻害剤及びそれを含む食品 |
JPH11292752A (ja) * | 1998-04-13 | 1999-10-26 | Lion Corp | 美白剤及び皮膚外用組成物 |
Non-Patent Citations (3)
Title |
---|
BIANCHI G. ET AL.: "Pentacyclic triterpene acids in olives", PHYTOCHEMISTRY, vol. 37, no. 1, 1994, pages 205 - 207, XP002941718 * |
MANEZ S. ET AL.: "Effect of selected triterpenoids on chronic dermal inflammation", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 334, 1997, pages 103 - 105, XP002941720 * |
RECIO M.C. ET AL.: "Structual requirements for the anti-inflammatory activity of natural triterpenoids", PLANTA MED., vol. 61, 1995, pages 182 - 185, XP002941719 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002043736A1 (fr) * | 2000-11-30 | 2002-06-06 | The Nisshin Oillio, Ltd. | Aliments et boissons embellissants et preparations perorales embellissantes |
JP2005082522A (ja) * | 2003-09-08 | 2005-03-31 | Kanebo Cosmetics Inc | 美白化粧料 |
JP2005179285A (ja) * | 2003-12-22 | 2005-07-07 | Lotte Co Ltd | ヒスタミン遊離抑制剤及びそれを含む飲食品 |
JP4491065B2 (ja) * | 2003-12-22 | 2010-06-30 | 株式会社ロッテ | ヒスタミン遊離抑制剤 |
WO2005067885A1 (en) * | 2004-01-15 | 2005-07-28 | Amorepacific Corporation | Skin whitening composition having synergic whitening effect |
US7718635B2 (en) | 2005-06-10 | 2010-05-18 | Pola Chemical Industries Inc. | Triterpenic acid derivative and preparation for external application for skin comprising the same |
WO2006132033A1 (ja) * | 2005-06-10 | 2006-12-14 | Pola Chemical Industries Inc. | 新規トリテルペン酸誘導体及びそれを含有してなる皮膚外用剤 |
JP5080249B2 (ja) * | 2005-06-10 | 2012-11-21 | ポーラ化成工業株式会社 | 新規トリテルペン酸誘導体及びそれを含有してなる皮膚外用剤 |
CN101193907B (zh) * | 2005-06-10 | 2012-07-11 | 宝丽化学工业有限公司 | 三萜酸衍生物和包含其的皮肤外用剂 |
JP2007332066A (ja) * | 2006-06-14 | 2007-12-27 | Nikko Chemical Co Ltd | チロシナーゼ産生抑制剤 |
JP4528745B2 (ja) * | 2006-06-14 | 2010-08-18 | 日光ケミカルズ株式会社 | チロシナーゼ産生抑制剤 |
JP2007332088A (ja) * | 2006-06-16 | 2007-12-27 | Pola Chem Ind Inc | ベシクル系に好適な皮膚外用剤 |
JP2009542632A (ja) * | 2006-07-04 | 2009-12-03 | ウォンキソファーム カンパニー リミテッド | 新規な環式化合物の誘導体及びその用途 |
JPWO2008018118A1 (ja) * | 2006-08-07 | 2009-12-24 | 株式会社ノエビア | ネマガリダケ含有組成物、保湿剤、細胞賦活剤、美白剤及び抗酸化剤 |
JP5014343B2 (ja) * | 2006-08-07 | 2012-08-29 | 株式会社ノエビア | ネマガリダケ含有組成物、保湿剤、細胞賦活剤、美白剤及び抗酸化剤 |
JP2008074761A (ja) * | 2006-09-20 | 2008-04-03 | Naris Cosmetics Co Ltd | 化粧料 |
JP2009137846A (ja) * | 2007-12-04 | 2009-06-25 | Kyoei Kagaku Kogyo Kk | 化粧料 |
JP2010116350A (ja) * | 2008-11-13 | 2010-05-27 | Maruzen Pharmaceut Co Ltd | エンドセリン−1mRNA発現抑制剤、幹細胞増殖因子(SCF)mRNA発現抑制剤、塩基性線維芽細胞増殖因子(bFGF)mRNA発現抑制剤、及びプロオピオメラノコルチン(POMC)mRNA発現抑制剤 |
JP2011236150A (ja) * | 2010-05-10 | 2011-11-24 | Nippon Flour Mills Co Ltd | マスリン酸を有効成分とする抗アレルギー剤 |
JP2013010715A (ja) * | 2011-06-29 | 2013-01-17 | Nippon Flour Mills Co Ltd | う蝕予防剤、歯周病予防剤及び口腔用組成物 |
CN102552969A (zh) * | 2011-12-21 | 2012-07-11 | 深圳市宜丽环保科技有限公司 | 一种具有抑菌及美白功能的卫生护垫 |
WO2018066704A1 (ja) * | 2016-10-07 | 2018-04-12 | 国立大学法人 九州大学 | メラニン抑制剤、抗菌剤、抗アレルギー剤、コラーゲン生成促成剤および保湿剤 |
Also Published As
Publication number | Publication date |
---|---|
CA2404012A1 (en) | 2001-10-04 |
EP1295587A1 (en) | 2003-03-26 |
US20030133958A1 (en) | 2003-07-17 |
AU4468201A (en) | 2001-10-08 |
KR20030005252A (ko) | 2003-01-17 |
JPWO2001072265A1 (ja) | 2004-03-18 |
CN1427707A (zh) | 2003-07-02 |
JP3958968B2 (ja) | 2007-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3958968B2 (ja) | 皮膚外用剤及び美白剤 | |
AU768306B2 (en) | Skin-care agents, skin antiaging agents, whitening agents and external skin preparations | |
KR100970544B1 (ko) | 피부외용제용 조성물 및 그의 사용방법 | |
JP4091825B2 (ja) | 皮膚外用剤 | |
JPH0648934A (ja) | 皮膚外用剤 | |
JP4091824B2 (ja) | 皮膚外用剤 | |
CA2430346A1 (en) | Beautifying foods and drinks and peroral beautifying preparations | |
JP2001261570A (ja) | 皮膚外用剤 | |
JP2008247839A (ja) | カルコン配糖体を含む抗酸化剤 | |
JP2012001467A (ja) | 皮膚外用剤 | |
JP2003063925A (ja) | 皮膚外用剤 | |
JP2001181198A (ja) | 美肌剤、皮膚の抗老化剤、美白剤および皮膚外用剤 | |
JPH0558870A (ja) | 美白用化粧料組成物 | |
JP4350331B2 (ja) | コラーゲン産生促進剤、コラゲナーゼ阻害剤、線維芽細胞増殖作用剤及び皮膚化粧料並びに美容用飲食品 | |
JP3754646B2 (ja) | 皮膚外用剤 | |
KR20180090123A (ko) | 리퀴댐버릭 락톤을 포함하는 화장료 조성물 | |
JP2003176230A (ja) | コラーゲン産生促進剤、エラスターゼ阻害剤、コラゲナーゼ阻害剤及び皮膚化粧料並びに美容用飲食品 | |
JP2003146838A (ja) | 皮膚化粧料及び美容用飲食品 | |
JP2005104886A (ja) | コラーゲン合成促進剤、線維芽細胞増殖促進剤、サイクリックampホスホジエステラーゼ阻害剤、チロシナーゼ阻害剤、及び血小板凝集抑制剤、並びに化粧料及び飲食品。 | |
JP2002060337A (ja) | 皮膚外用剤 | |
JP7451005B1 (ja) | ヘレナリン誘導体を含有する前駆脂肪細胞の増殖及び/又は分化促進剤 | |
JP2003176232A (ja) | 皮膚外用剤及び飲食品 | |
KR20180061662A (ko) | 아네모시드 a3을 포함하는 화장료 조성물 | |
JP3502826B2 (ja) | 皮膚外用剤 | |
JP2002193820A (ja) | 皮膚外用剤及び皮膚外用剤組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 570227 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2404012 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027013053 Country of ref document: KR Ref document number: 10259323 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001244682 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001917726 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018088716 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027013053 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001917726 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020027013053 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001917726 Country of ref document: EP |